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ABSTRACT  
 
 
INTRODUCTION 
 
Human immunodeficiency virus type 1 (HIV-1) transactivator of transcription (tat) is a 
regulatory gene that encodes the transactivator of transcription Tat protein. The Tat 
effectively increases the activity of the HIV-1 5’ long terminal repeat (5’ LTR) viral 
promoter to transcribe viral genes. The tat gene has two exons; the first 72 amino acids 
of Tat are encoded by the first exon, whilst amino acids 73 – 101 are encoded by the 
second exon. Exon 1 of Tat is sufficient for the transactivation of the 5’ LTR and therefore 
was the focus of this study. The Tat encoded by exon 1 consists of 5 functional domains 
these include: the acidic domain (domain I) comprising amino acids 1 – 21, this is a proline 
rich domain with high sequence variation; the cysteine-rich domain (domain II) comprising 
amino acids 22–37, is composed of 6 well conserved cysteine residues in subtype C Tat 
proteins, a mutation at any of the 6 cysteine residue results in loss of Tat activity; the core 
domain (domain III) comprising amino acids 38–48, is made of a hydrophobic motif and 
is relatively well conserved. Together, the first 48 amino acids of Tat comprising domains 
I – III, allow for the transactivation activity of Tat responsible for enhancing viral gene 
transcription. The basic domain (domain IV) is an RNA-binding domain made up of amino 
acids 49 – 57 which allows for the binding ability of Tat to the TAR loop structure of the 5’ 
LTR. Lastly the glutamine-rich domain (domain V) comprised of amino acids 58 – 72, also 
concentrated with basic amino acids, has the highest sequence variation in Tat. During 
the early stages of infection, HIV-1 enters the central nervous system (CNS) and 
replicates at marginal levels compared to high viral replication in the periphery. Yet, there 
is higher HIV-1 RNA levels in the in the cerebrospinal fluid (CSF) compared to plasma of 
tuberculosis meningitis (TBM) co-infected patients. However, the mechanisms driving the 
higher viral replication in the CNS of TBM patients are not well understood. Therefore, 
the major aim of this study is to characterise genetic and functional diversity of CNS and 
plasma derived Tat from TBM coinfected patients. We hypothesized that TBM coinfected 
patients will display genetically distinct HIV-1 tat variants in the CSF as a driver or 
consequence of higher viral replication in this compartment compared to plasma. 
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METHODS 
 
Viral RNA was extracted from matched CSF and plasma samples obtained from 20 HIV-
1 chronically infected patients (17 TBM and 3 non-TBM) using the QIAmp viral RNA Mini 
kit (Qiagen Inc., Valencia, CA, USA). Extracted viral RNA was reverse transcribed into 
viral DNA using SuperScript IV Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) 
and amplified using two rounds of (nested) PCR with the Platinum ® Taq DNA 
Polymerase High Fidelity PCR kit (Thermo Fisher Scientific, Boston, MA, USA).  Genetic 
diversity of plasma and CSF derived isolates was assessed in 19 patients (16 TBM and 
3 non-TBM) by sequencing, neighbour-joining phylogenetic analysis and both interpatient 
and intrapatient diversity analysis. The Tat sequences with previously reported mutations 
that affect Tat function were selected for downstream functional assays. Twelve tat PCR 
amplicons were cloned into a pTargeT™ expression plasmid (Promega Corporation, 
Madison, WI). Recombinant pTargeT clones containing patient derived HIV-1 tat was 
propagated using the QIAfilter Plasmid Maxi Kit (Qiagen Inc., Valencia, CA, USA) to 
transfect the TZM-bl mammalian cells, which contains the luciferase gene luc under the 
control of the LTR promoter. A luciferase assay was done to measure the relative 
luminescence for each Tat mutant and this was correlated to markers of disease 
progression such as viral load. 
 
RESULTS 
 
The phylogenetic data from our study show that sequences from plasma and CSF derived 
HIV-1 tat clustered closely per patient. Genetic variation was seen as varying branch 
lengths between patient clusters. However, our data do not show significant nucleotide 
differences between the plasma and CSF tat sequences with a p-distance of 0.059 and 
0.062 respectively (p = ns). Additionally, our data revealed that the amino acid sequences 
were the same between the CSF and plasma compartments, except in 5% of patients 
that showed differences in positions that were not previously reported to affect Tat activity. 
However, Tat diversity was observed to occur in all 5 domains of the first 72 amino acids 
of Tat namely: V4I, P21A, K24S, H29R, S31C, S46Y, R52W, S57R, P59S and D64G. 
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The functional data from our study revealed that most patient derived Tat mutations 
occurred in combination with other previously reported mutations. Interestingly, Tat 
mutations that occurred together with P21A in five different patients showed a showed 
strong positive correlation with CSF viral load in the CNS (p = 0.003; r = 0.98).  
 
CONCLUSION 
 
We reject our hypothesis that CNS specific Tat mutations were responsible for the high 
viral load in the CNS of patients who have TBM, as the allele frequencies of reported 
amino acid substitutions were represented in equal proportions within plasma and CSF 
derived Tat variants. Furthermore, our functional data shows that majority of all Tat 
variants from the TBM group had a reduced capacity to transactivate the 5’ LTR. Whilst 
we cannot confirm that Tat is responsible for the higher viral replication seen in the CNS 
of TBM coinfected patients, our data demonstrate that all Tat variants with a P21A 
mutation significantly correlates to viral replication in the CNS. Future studies should 
perform site directed mutagenesis to determine the exact mutations that mediate LTR 
activity. 
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1.  Introduction 
 
In June 1981, the Centers for Disease Control and Prevention (CDC) had published a 
weekly report that described five cases of Pneumocystis carinii pneumonia (PCP) in 
homosexual North-American men (CDC, 1981a). The PCP infection is known for causing 
pulmonary inflammation and fluid buildup in the lungs. The five PCP cases were reported 
to be from non-related individuals who were all sexually-active homosexual men. 
Although all 5 men were reported to be using inhalant drugs, they were otherwise healthy 
(CDC, 1981a). However, PCP is an opportunistic infection, known to infect severely 
immunosuppressed individuals. At the time the report was published, two of the five men 
had died (CDC, 1981a). A subsequent report in July 1981, following the PCP incidence 
had described the occurrence of a rare malignancy known as Kaposi sarcoma (KS), found 
within 26 homosexual men (CDC, 1981b). The KS was described an aggressive cancer 
affecting elderly men. The KS cases began to spread, initially infecting  41 homosexual 
men – eight of which died in less than 2 years after being diagnosed (CDC, 1981b).  
 
In August 1981, a case definition was then established to control the outbreak of these 
infections. The case definition consisted of two criteria; (1) either persons acquiring 
opportunistic  infections with no known underlying illness or history of immunosuppressive 
therapy or (2) individuals over 60 years of age with a confirmed biopsy of KS. Although 
there were a few cases of heterosexual women fitting the case definition, due to majority 
of the cases being documented amongst homosexual men, the disease was termed Gay-
Related Immunodeficiency (GRID) (CDC, 1981b).  However during December 1981 and 
early 1982, due to the growing increase in case reports describing heterosexual 
populations infected with KS and other opportunistic infections, it became evident that the 
disease was not limited to the homosexual population and the CDC renamed the 
condition Acquired Immune Deficiency Syndrome or AIDS (CDC, 1982a, CDC, 1982b). 
Hence it was only in 1982, when the case definition for AIDS was first described. Whilst 
the cause of the condition was still unknown the AIDS pattern was characterized by low 
CD4+ T cell counts (below 200 cells/mm3), inflamed lymph nodes (lymphadenopathy) and 
susceptibility to opportunistic infections (CDC, 1982b). 
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Following the CDC’s case definition of AIDS in 1982, two independent research teams 
identified a novel retrovirus present in individuals with AIDS. In 1983 Montagnier and co-
workers isolated the Lymphadenopathy-associated virus (LAV) and characterized it as 
part of the Lentivirus genus, Retroviridae family (Barré-Sinoussi et al., 1983). Separately, 
Gallo and co-workers named it human T lymphotropic virus type III (HTLV-III) (Gallo et 
al., 1984). However in 1986, it was decided by the International Committee on Taxonomy 
of Viruses that the virus be renamed to Human Immunodeficiency Virus (HIV) (Francki et 
al., 1991). Subsequently both the Montagnier and Gallo groups provided integral 
information which revealed that HIV is the causative agent of AIDS. Since then, 
substantial research has been done on HIV, allowing for the development of laboratory 
and diagnostic tests used to detect HIV antibodies and biomarkers for HIV progression.  
 
1.1  The Epidemiology of HIV  
 
Since the discovery of HIV as the causative agent of AIDS (Barre-Sinoussi, 1983, Gallo 
et al., 1984), the HIV/AIDS pandemic has continued to grow on a global scale. According 
to the recent Joint United Nations Programme on HIV/AIDS (UNAIDS) 2018 global report, 
there were 36.9 million people living with HIV, 1.8 million new HIV infections and 940 000 
AIDS related deaths (UNAIDS, 2018). The HIV virus is categorized into two genetically 
distinct viral types: HIV type 1 (HIV-1) and HIV type 2 (HIV-2). While HIV-2 is 
geographically restricted to West Africa, HIV-1 is distributed worldwide (Lemey et al., 
2003). The HIV-1 virus is arranged into four distinct phylogenetic groups: Group M 
(major), group O (outlier), group N (non-major and non-outlier) (Hemelaar et al., 2006) 
and the recently identified  group P in Cameroon (Vallari et al., 2011). 
 
The Group M viruses are further divided into 9 different subtypes: A, B, C, D, F, G, H, J, 
K and 90 circulating recombinant forms (CRF’s)  (Foley B, 2017). The CRF’s are the 
product of the recombination of different viral subtypes that in essence form a new strain 
of the virus (Thomson et al., 2002). However, HIV-1 viral subtypes and CRF’s are not 
evenly distributed throughout the globe (Figure 1.1). 
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Figure 1:1 Global distribution of HIV-1 subtypes and circulating recombinant forms. 
The HIV-1 viral subtypes are distributed worldwide. Subtype A (blue) is commonly found 
in Eastern Europe, Central Asia and Central and Eastern Africa. Subtype B (green), is 
distributed in the Americas, Western Europe and Australasia. Subtype C (red) is found 
within India, Eastern and predominantly in Southern Africa. Subtype D (purple) is mainly 
present in East Africa while subtypes F, G, H, J, K as represented in turquoise are 
concentrated in West Africa. The CRF’s; CRF_01_AE (orange) are found in Southeast 
Asia and CRF_02_AG (yellow) in West Africa. Source: Adapted from (Santos and Soares, 
2010, Hemelaar, 2012). 
 
The HIV-1 subtype A predominates in Eastern Europe, Central Asia and Central and 
Eastern Africa, with a global prevalence of 12% (Taylor et al., 2008). The HIV-1 subtype 
B is widely distributed in the Americas, Western Europe and Australasia, however it only 
accounts for 10% of global infections. The HIV-1 subtype D is mainly present in East 
Africa and is associated with a rapid disease progression in Uganda, Kenya and Tanzania 
(Kaleebu et al., 2002). Although HIV-1 subtype D is more virulent it represents only 3% 
of global infections. Subtype G is mainly concentrated in West Africa, with a global 
prevalence of 6%. Whilst subtype F, H, J and K are scattered in various countries and 
represent a minor proportion of <1% of the global spread of HIV-1. The two major CRF’s 
making up a significant proportion of individuals infected are CRF01_AE and CRF02_AG 
which are found in Southeast Asia and West Africa respectively, and they account for 
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approximately 5% of the global prevalence of HIV-1. Whilst the African continent contains 
a heterogeneous mix of viral subtypes, HIV-1 subtype C found within India, Eastern Africa 
and predominantly in sub-Saharan Africa, is responsible for approximately 50% of global 
HIV-1 infections (Hemelaar et al., 2011). Hence the sub-Saharan African region bears the 
brunt of the HIV/AIDS pandemic (Thomson et al., 2002). Therefore, HIV-1 subtype C 
(HIV-1C) is the focus of this study. 
 
1.2  HIV-1 genome organisation  
 
The HIV-1 virus is a member of the Lentivirus genus, Retroviridae family and 
Orthoretrovirinae subfamily (Coffin et al., 1986a, Coffin et al., 1986b). The viral genome 
consists of two single stranded ribonucleic acid (RNA) molecules enclosed within the virus 
core (Kurth and Bannert, 2010). The integrated viral deoxyribonucleic acid (DNA), known 
as the provirus, is approximately 9.8 kilobases (kb) in length consisting of 9 genes, flanked 
by identical long terminal repeat (LTR) on both at the 5’ and 3’ end of the HIV-1 genome 
(Figure 1:2)(Freed, 2001). The HIV-1 genes are divided into three groups: structural, 
accessory and regulatory. There are three structural genes: group specific antigen (gag); 
polymerase (pol); and envelope (env), four accessory genes: viral protein U (vpu); viral 
protein R (vpr); viral infectivity factor (vif) and negative regulation factor (nef). Lastly two 
regulatory genes: regulator of virion expression (rev) and transactivator of transcription 
(tat) each comprising two exons (Kuiken et al., 1999). Moreover, the first exon of tat have 
open reading frames (ORF) which partially overlap with vpu and rev (Fernandes et al., 
2016). 
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Figure 1:2 HIV-1 genome organisation. The HIV-1 provirus genome is approximately 
9.8kb, consisting of 9 genes flanked by long terminal repeats (red) on either end. 
Structural genes; gag, pol and env (orange, yellow and light blue), accessory genes; vpu, 
vpr, vif (grey), and nef (dark blue) and two regulatory genes; rev and tat (pink and green) 
each gene comprising of two exons. Source: Adapted from (Suzuki and Suzuki, 2011, 
http://www.hiv.lanl.gov, 2018) 
 
The HIV-1 genome has 15 proteins encoded by 9 overlapping genes (Frankel and Young, 
1998). The Gag protein encoded by gag is a polyprotein encoding the inner structural 
proteins of the virus – the matrix (p17), capsid (p24) and nucleocapsid (p7) responsible 
for mediating viral assembly (Frankel and Young, 1998). The Pol polyprotein encoded by 
pol gets cleaved into three constituent viral enzymes; protease (prot), reverse 
transcriptase (p51) and integrase (p31) (Frankel and Young, 1998). The Env glycoprotein 
(gp) encoded by env is a gp160 protein gets processed into gp120 surface protein (SU) 
and gp41 transmembrane protein (TM) making up the structural components of the outer 
viral envelope (Frankel and Young, 1998). In addition, the accessory proteins Vpu, Vpr, 
Vif and Nef encoded by vpu, vpr, vif and nef respectively, are responsible for particle 
infectivity and release of HIV-1 virions from the infected cell. Lastly two regulatory proteins 
Rev encoded by rev is responsible of nuclear export of viral messenger RNA (mRNA) into 
the cytoplasm and Tat encoded by tat whose function is enhancing viral transcription 
(Frankel and Young, 1998). The Tat protein is the focus of this study and will be discussed 
further below.  
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1.3  The HIV-1 Replication cycle 
 
To establish infection the virus follows a replication cycle which includes: binding and 
entry, reverse transcription, integration, transcription, translation, assembly, budding and 
virion maturation (Figure 1:3) (Freed, 2001). In summary, following cell entry the viral 
genome RNA is reverse transcribed to form double-stranded DNA, which is integrated 
stably into chromosomal DNA also known as a provirus (Fauci, 1988).  
 
Entry of HIV-1 into target cells occurs through the binding of the HIV-1 surface envelope 
glycoprotein gp120 to the CD4+ antigen receptor protein on the surface of the susceptible 
host cell (Ferguson et al., 2002). In addition to the CD4+ receptor there is also a co-
receptor on the host cell, which differs for host cell types. The  C-C chemokine receptor 
5 (CCR5) protein commonly found on a subset of helper T lymphocytes, monocyte-
macrophages dendritic cells, and Langerhans cells whereas the CXC chemokine receptor 
4 (CXCR4) protein found on T cells subsets (Freed, 2001). This high affinity receptor and 
co-receptor binding results in the fusion of the viral and cellular membranes, mediated by 
glycoprotein gp41. Thus, allowing the viral core composed of p17 matrix protein and the 
p24 capsid protein to enter the cytoplasm of the susceptible cell (Freed, 2001). 
 
Subsequent to entry, the uncoating process of the viral core allows for the release of two 
identical viral RNA copies and viral proteins including the three viral enzymes; reverse 
transcriptase (RT), integrase (IN) and protease (PR) into the cytoplasm of the infected 
cell. Once inside the cell, the HIV-associated RT directs the synthesis of single stranded 
DNA copy from the viral RNA genome in a process known as reverse transcription 
(Kuiken et al., 1999). During DNA synthesis, the ribonuclease H (RNase H) domain from 
RT degrades the RNA strand and produces RNA primers which are used to synthesize 
complimentary DNA, resulting in a double stranded DNA molecule (Boyer et al., 2018). 
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Figure 1:3: HIV-1 replication cycle. The HIV-1 replication cycle described in 4 major 
steps: Binding and entry whereby HIV-1 enters the cell through receptor-coreceptor 
binding and fusion of viral and cellular membranes; reverse transcription and integration 
of the viral RNA into proviral DNA; replication and assembly of mRNA into viral proteins 
and lastly budding of newly made viruses (intracellular) and maturation of virions 
(extracellular). Source: Adapted from (Freed, 1998, Kirchhoff, 2013). 
 
The resulting double stranded DNA then moves into the nucleus and is inserted into the 
host chromosome by integrase (IN) with cellular proteins including but not limited to the 
Lens Epithelium-derived Growth factor (LEDGF/p75), helping in tethering the HIV-1 DNA 
and proteins to the chromatin (Christ and Debyser, 2013). Subsequently, the integrated 
proviral DNA and cellular DNA are replicated through cell division cycles. With the proviral 
DNA acting as a template for viral gene transcription. Transcription is initiated in the 5’ 
LTR of the provirus. The viral LTR element consists of 3 regions (U3, R and U5) each 
involved in transcription. Transcription is mediated by the host-cell RNA polymerase II 
and upregulated by the viral transactivator of transcription protein (Tat) yielding numerous 
copies of viral genome messenger RNA (mRNA)(Coffin et al., 1997). The transactivation 
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(enhancing) ability of Tat in HIV-1 transcription will be discussed subsequently in detail 
as it is the focus of this study. 
 
The newly synthesized viral mRNA is then transported into the cytoplasm where it is 
spliced and translated, producing viral enzymes and structural proteins (Coffin et al., 
1997). Some of the structural proteins are formed by cleavage of a long polyprotein by 
the PR (Gomez and Hope, 2005). Assembly of the virus commence when core structural 
proteins; p17 matrix protein and the p24 capsid protein encapsulate the newly formed 
viral RNA genome with a viral capsid. Viral glycoproteins gp120 and gp41, which will 
eventually form the viral envelope, are transported to the surface of the cell through 
cellular secretory mechanisms (Gomez and Hope, 2005). 
 
Budding occurs when the viral capsid extrudes out of the cell membrane of the infected 
cell. This process is mediated by Gag and the host cellular endosomal sorting complexes 
required for transport (ESCRT) pathway (Sundquist and Kräusslich, 2012). Briefly, viral 
budding occurs in two stages: (1) membrane deformation, whereby a plasma membrane 
is wrapped around the nascent virion and (2) membrane scission, whereby the newly 
formed bud is detached from the host membrane (Votteler and Sundquist, 2013). The 
combination of these steps is required for virion release and maturation. Virion maturation 
is mediated by viral PR, allowing for cleavage of structural proteins and viral enzymes 
which results in the formation of an infectious virion (Sundquist and Kräusslich, 2012). 
 
1.4  Structure and Function of HIV-1 Tat 
 
As aforementioned, the tat gene encodes Tat, whose length varies between 86 – 101 
amino acids in length, with the predominant form of Tat being 101 residues (Jeang, 1996). 
The structure of Tat will be discussed in section 1.4.1. The Tat protein plays a crucial role 
in the upregulation of viral gene transcription by transactivating the 5’ LTR viral promoter. 
The transactivation activity of Tat occurs upon binding to its RNA target, the 
transactivation response element (TAR), located in the 5′ LTR (Dingwall et al., 1989). The 
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function of Tat will be discussed in section 1.4.2. In addition to its transactivation activity, 
Tat has both chemotactic and neurotoxic which contribute to its pathogenesis. 
 
The viral Tat functions at an intracellular and extracellular level as reviewed by (Chiozzini 
and Toschi, 2016). The Tat proteins produced within an HIV infected cell allows for of 
viral gene expression by transactivating the 5’ LTR. In addition, other non-transcriptional 
functions of  intracellular Tat include HIV-1 RNA splicing, capping, translation, and 
reverse transcription (Das et al., 2011). Whilst, extracellular Tat is involved in modulating 
cellular gene expression allowing for; apoptosis, cytokine dysregulation, and neurotoxicity 
all of which contribute to its role in HIV-1 pathogenesis. The neurotoxic activity of Tat 
stems from its ability to travel along neuronal pathways as a single protein molecule and 
infect various central nervous system (CNS) cells. Several neuropathogenesis studies 
have reported the presence of Tat and elevated expression of its mRNA in the CNS of 
patients with HIV-1 encephalitis (HIVE) and HIV-1-associated dementia (HAD) (Cowley 
et al., 2011). However, the transactivation ability of Tat will be further described in this 
chapter as it is the focus of the study. 
 
1.4.1 The structure of HIV-1 Tat  
 
The Tat protein is approximately 86 – 101 amino acids (aa) in length (Jeang, 1996). The 
predominant form of Tat found in clinical isolates is 101 aa in length (Figure 1:4) (Zhang 
et al., 2014). The first 72 amino acids of Tat (aa: 1-72) are encoded by the first exon of 
the HIV-1 tat gene and are sufficient for the transactivation of the viral 5’ LTR (Jeang, 
1996).  These 72 amino acids are divided into 5 domains. An N-terminal acidic domain 
(domain I) comprising aa: 1 - 21 of Tat, this is a proline rich acidic domain with 6 proline 
residues. This domain has been reported to tolerate mutations well, with only Tryptophan 
11 (W11) that is conserved (Campbell and Loret, 2009). A cysteine rich domain (domain 
II) consisting of aa: 22–37, with seven well conserved cysteine amino acids at positions 
22, 25, 27, 30, 31, 34 and 37, except in subtype C where a C31S mutation is more 
frequently observed (Campbell and Loret, 2009). Aside from the C31S mutation, a 
mutation at any one of the cysteine sites will result in a non-functional Tat (Kameoka et 
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al., 2002). Domain III with aa: 38–48 is the core domain, containing a conserved 
Phenylalanine (F38) and amino acid sequence LGISYG (Campbell and Loret, 2009). 
Hence, the first three domains, composed of the first 48 amino acids of Tat form the Tat 
activation domain that is responsible for the transcriptional elongation and binding to 
Cyclin T1 (Tahirov et al., 2010).  
 
 
Figure 1:4: The structure and functional domains of Tat. The Tat protein is 
approximately 86-101 amino acids in length and consists of 5 functional domains that are 
encoded by exon 1. These include the acidic domain (red), cysteine-rich domain (orange), 
core domain (yellow) made of a hydrophobic motif, basic domain (green) is an RNA-
binding domain (RBD) and a glutamine-rich domain (light blue). The first 48 amino acids 
allow for the transactivation activity of Tat via Cyclin T1 (CycT1) binding which is 
responsible for enhancing viral transcription. The basic domain made up of amino acids 
49 – 57 is the RNA binding domain (RBD) which allows for the binding ability of Tat to the 
TAR loop structure of the 5’ LTR allowing for transactivation of viral transcription. Both 
the basic and glutamine-rich domains are concentrated with basic amino acids, this basic 
region is also responsible for nuclear localization of Tat. Domain VI which is encoded in 
exon 2 (dark blue) is comprised amino acids 73 – 101 which allow for integrin binding of 
Tat. Adapted from: (Li et al., 2012, Jeang, 1996). 
 
Domain IV, is the basic domain, made of aa: 49–57 which has a well conserved 
RKKRRQRR basic amino acid sequence. This domain is also known as the RNA binding 
domain (RBD), responsible for the binding ability of Tat to the transactivation response 
(TAR) element found in the 5' LTR, viral promoter (Bagashev and Sawaya, 2013). Domain 
V, consisting of aa: 60–72, forms the glutamine-rich domain – which also has high 
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sequence variation. The second exon of Tat (Domain VI), composed of amino acids 73 – 
101 in the C-terminus of Tat is not well studied. Although the function of the second exon 
of Tat is still unclear, it has been implicated to contribute towards overall optimal 
transactivation and transrepression of Tat allowing for increased infectivity (Jeang, 1996). 
Furthermore exon 2 contains an arginine-glycine-aspartic acid (RGD) motif which 
supports integrin binding and signalling allowing for increased cellular update of Tat 
(Vogel et al., 1993). 
 
1.4.2 Mechanism and Function of Tat  
 
The primary function of Tat is to enhance viral gene transcription by binding to the TAR 
element located at the 5' LTR, viral promoter. The binding of Tat to the TAR element 
allows for the elongation of RNA polymerase II (Pol II) through the recruitment of various 
transcription factors that will in turn increase the processivity of transcription (Lu et al., 
2013). In the absence of Tat, viral gene transcription is significantly inhibited due the loss 
of Pol II processivity allowing mRNA to separate from the DNA template prematurely 
(Karn, 2000). 
 
1.4.2.1 Transcription initiation from the HIV-1 core promoter region  
 
Transcription is initiated at the first nucleotide (+1) in the R region of the HIV-1 5’ LTR (5’ 
LTR). The 5’ LTR alone is capable of initiating and driving basal gene transcription – albeit 
a low level in the absence of Tat, resulting in short abortive viral mRNA transcripts 
(Lassen et al., 2004). Transactivation of transcription is primarily due to the presence of 
Tat (Karn, 2000). Briefly, initiation of HIV-1 transcription occurs when Pol II binds to the 
core promoter region of the 5’ LTR, which is inclusive of: the TATA box, initiator (Inr) at 
the transcription start site +1, downstream core promoter element (DPE) and transcription 
factor B (TFIIB) that is bound to the B recognition element (BRE) (Butler and Kadonaga, 
2002). These core control elements allow for the assembly of basal transcription proteins. 
A preinitiation complex (PIC) is formed , through the binding of the transcription factor II 
D (TFIID) to the TATA box in the core promoter region (Ne et al., 2018). This is followed 
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by five more TF’s (TFIIA, TFIIB, TFIIE, TFIIF, and TFIIH) binding to the Pol II. The 
combined complex is able to facilitate transcription initiation (Ne et al., 2018).  
 
Whilst basal transcription (in the absence of Tat) is only able to effectively initiate 
transcription, elongation is defective (Karn, 2000). Consequently, a Tat-mediated 
transcription allows for an effective elongation, following viral transcription initiation. Thus, 
ensuring that the full-length viral mRNA is transcribed and processed to make the 
necessary proteins. Hence Tat resumes transcriptional control solely at the elongation 
stage of HIV-1 transcription.  
 
1.4.2.2 A Tat mediated elongation  
 
As aforementioned in the absence of Tat, viral mRNA transcription is effectively initiated 
but Pol II only processes short abortive mRNA transcripts, this is due to the pause in 
transcription that is induced by the DRB sensitivity-inducing factor (DSIF) and negative 
elongation factor (NELF) soon after the transcriptional start site (+1) (Figure 1:5) (Zhou 
and Rana, 2002).  This negative feedback loop occurs in basal conditions, preventing Pol 
II to proceed into elongation (Nilson and Price, 2011). Moreover, the pre-mRNA 3'-end 
processing factor (Pcf11) reinforces this block in elongation by prematurely terminating 
the transcription of the short nascent viral mRNA products –  resulting in abortive mRNA 
transcripts (Natarajan et al., 2013). Histone deacetylases (HDAC) are also recruited to 
the paused complex to further reinforce a transcriptionally repressed chromatin state 
(Zhou and Rana, 2002). 
 
This transcriptionally repressed state is relieved upon Tat binding to the TAR element in 
the in the R region of the 5' LTR, allowing for the elongation of Pol II (Lu et al., 2013). 
Hence, Tat specifically recognizes the TAR RNA loop and binds to a uridine-rich (U-rich) 
bulge in the apex of the loop (Dingwall et al., 1989).  
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Figure 1:5 Model for Tat mediated HIV-1 LTR activation of RNA polymerase II. 
Transcription is initiated at the promoter region of HIV-1 5’ LTR. The 5’ LTR is capable of 
driving a basal gene transcription, however during basal conditions Pol II is only 
processed a short distance downstream from the transcriptional start site when the DRB 
sensitivity-inducing factor (DSIF; yellow) and negative elongation factor (NELF; red) 
induce a pause in transcription – creating a negative feedback loop. This transcriptionally 
repressed state is relieved upon the binding of the Tat protein to the 5’ LTR. Tat establishes 
a positive feedback loop, upon binding to the transactivation response (TAR) element. 
Once Tat is bound to the TAR stem loop structure, it recruits positive transcription 
elongation factor (P-TEFb; grey), composed of CDK9 (blue) and Cyc T1 (orange), which 
drives the phosphorylation of the CTD allowing for transcriptional activation from the HIV-
1 LTR. Tat mediates hyperphosphorylation of the CTD relieving the negative feedback 
loop. Hyperphosphorylation of the CTD allows for enhanced transcription. Source: 
Adapted from (Zhou and Yik, 2006, Liu et al., 2014). 
 
Once Tat is bound to the TAR element, it mediates the recruitment of positive transcription 
elongation factor (P-TEFb). The P-TEFb ternary complex is composed of the catalytic 
subunit cyclin-dependent kinase 9 (CDK9), and the regulatory subunit Cyclin T1 (Cyc T1), 
that drive the phosphorylation of the C-terminal domain (CTD) of Pol II, allowing for 
activation of transcriptional elongation from the HIV-1 LTR (Karn and Stoltzfus, 2012). 
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Hence phosphorylation of the Pol II CTD are controlled by kinases (CDK9, Cyc T1)  which 
allow for regulation of viral transcription (Francis et al., 2011).  The CTD of Pol II is the 
combination of multiple heptad repeats of amino acids (tyrosine 1 – serine 2 – proline 3 – 
threonine 4 – serine 5 – proline 6 – serine 7), whose phosphorylated state is crucial to its 
activity, and therefore maintained until transcription termination (Ne et al., 2018).  
 
Once P-TEFb mediates hyperphosphorylation of the CTD of Pol II, the negative feedback 
loop (DSIF and NELF) is relieved from the complex (Karn and Stoltzfus, 2012). This 
allows for the recruitment of chromatin remodeling machinery such as histone 
acetyltransferases (HATs) which displace blocked nucleosomes and facilitates 
acetylation allowing nucleosomes to become more accessible (Ne et al., 2018). 
Ultimately, supporting transcription elongation of Pol II. 
 
1.5 Genetic variation in Tat 
 
Following infection, HIV-1 is characterized by a great degree of genetic diversity – due to 
a high mutation rate caused by error prone viral reverse transcriptase (RT), recombination 
and host factor proteins such as APOBEC 3G (Sanjuán and Domingo-Calap, 2016). 
Additionally a high replication rate, lifelong infection and large numbers of infected 
individuals all contribute to the circulation of different strains of the virus (Lidsky et al., 
2017). Previous studies have shown that Tat variation within subtypes have significantly 
affected its transactivation ability (Kurosu et al., 2002, Roy et al., 2015, Rossenkhan et 
al., 2013). Consequently, functional variation of the protein leads to varying degrees of 
pathogenesis. Whilst HIV-1C is responsible for over 50% of global infections, there is 
limited information available for the transactivation abilities of subtype C Tat isolates.  
 
One of the major HIV-1C studies showed that genetic variation within Tat was responsible 
for a significant change in the transcriptional activity of the viral LTR (Rossenkhan et al., 
2013). The Essex group were able to show that HIV-1C Tat diversity within aa: 1 – 72 
results in varying transactivation potential during primary infection which positively 
correlated with correlated with viral load (Rossenkhan et al., 2013). Whilst minimal genetic 
diversity and high homogeneity was observed in their phylogenetic analysis, they further 
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explored a mixed-effects model of evolution (MEME) to determine if any specific Tat 
residues were under positive selection. A preceding study that performed a signature 
pattern analysis identified five amino acid positions in Tat (21A, 24N, 29K, 40K, and 60Q) 
that contained signature residues unique for Indian HIV-1C (Neogi et al., 2012). However, 
the MEME analysis by the Essex group showed that residues; 3P, 4V, 21A, 24N, 29K, 
39I, and 68L of Tat exon 1 were positively selected in African HIV-1C. Furthermore, site 
directed mutagenesis in the first exon of Tat was performed to determine the functional 
effects of these residues undergoing positive selection.  As mentioned previously, tat 
exon 1 has an overlapping ORF with genes vpu and rev. Whilst there is paucity of data 
regarding the overlapping nature of non-structural genes, it should be noted that the 
MEME analysis done by the Essex group showed no evidence of positive selection 
mutations as a result of overlapping within Tat. Interestingly, the majority of the mutations 
were associated with a decrease in LTR transcription activity of Tat namely; E2D, V4I, 
P21A, K24S, L35Q, Q39L, P59S and P68S (Rossenkhan et al., 2013). Additionally, they 
examined patient derived Tat, due to the relative compensatory mutations that can occur 
when individual deleterious mutations occur in a natural infection. In the patient derived 
Tat isolates, the largest decrease (80%) in Tat activity was seen in a patient who had both 
E2D and P68L mutations. Conversely the largest increase was seen in a patient having 
both with a V4I and H29R that significantly upregulated LTR activation by 73%. Therefore, 
compensatory mutations in patient derived Tat could allow for a greater alteration in the 
functional capacity of Tat. 
 
1.6 HIV-1 Tat in the Central Nervous System  
 
The HIV-1 virus enters the CNS early in infection, by migrating across the blood brain 
barrier (BBB)(An et al., 1999). The mechanism of entry has been widely described as the 
‘Trojan horse’ model, since the CNS is tricked into allowing HIV-1 infected monocytes, 
macrophages, lymphocytes, endothelial cells as well as free virions passed the BBB 
(González-Scarano and Martín-García, 2005). However, viral replication is marginally 
lower in the CNS due to the cellular tropism of HIV-1 target cells (Martín-García et al., 
2006). Since neurons are not susceptible to HIV‐1 infection the virus actively replicates 
in macrophages, whilst astrocytes that harbor the virus aren’t able to actively replicate 
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(Russell et al., 2017). Although a previous report showed that astrocyte activation can be 
triggered by neurotoxic proteins like Tat, allowing for the in vitro expression of Tat from 
astrocytes (Zhou et al., 2004). Additionally the virus is able to persist latently within the 
long lived cells (e.g. astrocytes) of the CNS whose half-lives range from months to years 
and even a lifetime (Gray et al., 2016). Furthermore the CD4+ T helper cells (Th) found in 
the CNS are very few and do not actively replenish as the removal of large amounts of 
HIV-1 infected cells from the CNS may cause further neurological damage (Gray et al., 
2016). 
 
Although there is evidence that during mono-infection HIV-1 is able to evolve 
independently from non-CNS compartments, this finding is highlighted in HIV associated 
CNS disorders (Ene, 2018).  Thus a repertoire of CNS disorders including; opportunistic 
infections, immune reconstitution inflammatory syndrome (IRIS) and HIV-associated 
neurocognitive disorders (HAND) (Ene, 2018) has resulted in sequence 
compartmentalization between the CNS and non-CNS compartments at the level of HIV-
1 Env, Nef and Tat as reviewed by Gray et al., 2016. However, it is unclear if the source 
of compartmentalized HIV-1 is the result of an early seeded virus population or 
independent viral evolution in the CNS. 
  
A study by Cowley et al., (2011) found distinctive sequence variations when comparing 
HIV-1 tat nucleotide sequences derived from CNS and non-CNS compartments of 
patients with HIV-1 associated dementia (HAD). This group further demonstrated that Tat 
amino acid variation predominated within the Tat activation domain and the basic domain 
(Cowley et al., 2011). This Tat variation could possibly explain the heterogeneity in the 
ability of different Tat variants to transactivate the viral promoter, 5’ LTR (Cowley et al., 
2011). Viral variants causing the distinct genetic compartmentalization in the CNS 
suggest that differing selection pressures are acting on HIV-1 within and outside the CNS 
(Ohagen et al., 2003). 
 
Many studies suggest that immune selection pressures in the CNS are the result of 
upregulated inflammatory cytokine responses mediated by Tat through various signaling 
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cascades (Rappaport et al., 1999, Deshmane et al., 2009, Cupp et al., 1993). As 
previously mentioned, Tat activates many cellular genes in addition to the HIV-1 LTR, 
these include: tumor necrosis factor alpha (TNF-α), transforming growth factor beta 1 
(TGFβ-1), interleukin-2 (IL-2), interleukin-6 (IL-6) and interleukin-10 (IL-10) in cells of the 
CNS leading to dysregulation of cytokine expression (Sawaya et al., 1998). During CNS 
inflammation, pro-inflammatory cytokine TNF-α levels are elevated once macrophages 
and monocytes are exposed to Tat (Haij et al., 2015). Furthermore the upregulation of 
TNF-α expression increases the permeability of the BBB creating a paracellular route for 
HIV‐1 infected macrophages and monocytes to invade the CNS (Brabers and Nottet, 
2006, Rappaport et al., 1999). In addition Tat is able to synergistically work with TNF-α to 
enhance the T Helper Cell Type 2 (Th2) cytokine, IL-6 secretion and activate CNS 
endothelial cells (Bagashev and Sawaya, 2013, Chen et al., 1997). Elevated levels of IL-
6 can be correlated with stages of HIV disease progression (Li et al., 2010).  Another Th2 
cytokine induced by Tat is IL-10 (an anti-inflammatory cytokine) which is expressed in 
microglial and astrocytes cells during bacterial or viral invasion (Brabers and Nottet, 
2006). Usually IL-10 is produced to repair damages caused by excessive inflammation, 
high levels of IL-10 allow for inhibition of HIV replication (Naicker et al., 2009). On the 
contrary IL-10 single nucleotide polymorphisms in the proximal promoter region is 
associated with lower IL-10 production and a faster progression to AIDS (Naicker et al., 
2009). Hence IL-10 serves as a feedback regulator to stop overproduction of cytokines; 
IL-6 and TNF-α, interleukin-8 (IL-8), interleukin-12 (IL-12), or even IL-10 itself which aids 
in the development of chronic inflammation. However during CNS inflammation a state of 
immune dysregulation rises and Tat induces the extensive production of both IL-6 and IL-
10 (Li et al., 2010). 
 
1.7 HIV-1 and tuberculosis meningitis (TBM) co-infection 
 
Tuberculosis (TB) caused by Mycobacterium tuberculosis (M. tb) is the most acquired 
opportunistic infection in HIV/AIDS patients (Bruchfeld et al., 2015). The burden of the 
HIV and TB co-epidemic and low socioeconomic status in sub-Saharan Africa – make 
HIV vaccine development a priority. Furthermore, in hyperendemic settings such as the 
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sub-Saharan Africa region, disease progression to AIDS is often accompanied by 
opportunistic infections including but not limited to TB, which increase the morbidity and 
mortality in HIV-1 infected individuals. According to the recent World Health Organization 
(WHO) epidemic update, an estimated 40% of AIDS deaths were due to TB (WHO, 2018). 
Additionally, HIV-1 infected individuals with active TB have a high risk of extra pulmonary 
forms of tuberculosis (Thwaites et al., 2005).  
 
Tuberculosis meningitis (TBM) is the most severe extrapulmonary manifestation of TB, 
caused by the haematogenous spread of TB from the primary source of infection, usually 
the lungs (García-Moncó and Rodriguez-Sainz, 2018). As a result TBM is associated with 
a high mortality rate and severe neurological consequences (Faksri et al., 2018). Whilst 
the incidence of TBM in sub-Saharan Africa is still uncertain due to lack of diagnostic 
tools, a report by Patel et al., (2013) observed that approximately 10% of TB patients 
experience TBM in KwaZulu-Natal, South Africa (Patel et al., 2013). 
 
Furthermore, in an HIV-1 and TB co-infection both diseases become exacerbated, 
especially when TB is disseminated to the CNS  (Be et al., 2009). Whilst the cause of TB 
in the CNS is not well described, the high HIV-1 replication in the CNS results in viral 
diversity, which impacts its replication capacity (Seipone et al., 2018). To the best of our 
knowledge, the effect of HIV-1 tat genetic variation on the modulation of viral transcription 
in the CNS of TBM patients has not been studied. Thus, understanding the effects of HIV-
1 tat genetic variation on viral gene transcription in matched lymphoid and CNS 
compartments of TBM versus non-TBM patients will enhance our understanding of HIV-
1 replication in the CNS. Moreover, understanding the mechanisms that drive high HIV-1 
replication in vivo could provide valuable information which could guide the design of 
interventions aimed at HIV-1 cure and [or] remission. 
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1.8 Hypothesis 
 
We hypothesize that CNS derived HIV-1 Tat may display CNS specific mutations that 
may mediate higher viral replication in the CNS compartment of TBM co-infected patients. 
 
1.9 Aim 
 
The purpose of this project was to characterize the effect of CNS derived HIV-1 tat genetic 
variation and functional activity on viral replication in this compartment from TBM and 
non-TBM patients. 
 
1.10 Objectives  
 
1.10.1 To amplify and sequence CNS and plasma derived HIV-1 tat obtained from TBM 
and non-TBM patients in order to study genetic variation between these 
compartments. 
 
1.10.2 To perform a Tat transactivation assay to study the transactivation ability of 
different Tat variants. 
 
1.10.3 To correlate Tat mutations with markers of disease progression such as viral load 
in the CNS. 
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2. Methodology 
 
2.1.  Study Population  
 
A total of 20 study participants were selected from a larger prospective cohort of 235 TBM  
patients, as previously described (Patel et al., 2013). Using non-probability (purposive) 
sampling, 17 of 108 HIV+ samples with a high CSF viral load was taken from the TBM 
group. Whilst 3 out of 70 HIV+ samples with a low viral load in the CSF was taken from 
the non-TBM group. 
   
Briefly, all patients in the cohort were clinically assessed for tuberculosis meningitis; by 
having a computerized tomography (CT) scan done to remove contraindications to lumbar 
puncture. Plasma samples taken from patients underwent routine laboratory testing 
including: diagnostic syphilis test by fluorescent treponemal antibody absorption (FTA-
ABS), venereal disease research laboratory test and screening for HIV by enzyme-linked 
immunosorbent assay (ELISA) and CD4+ count. Additionally, 15ml of cerebrospinal fluid 
(CSF) samples collected by lumbar puncture, were subjected to routine tests such as: 
testing for acid-fast bacilli by gram staining, fluorescent staining using auramine, 
Mycobacteria testing using BD BactecMGIT 960, detection of Mycobacterium 
tuberculosis (M.tb) using the Roche Amplicor Mycobacterium Tuberculosis PCR Test, 
and fungal culture testing using a cryptococcal latex agglutination test. Subsequently, the 
CSF samples were analyzed by routine chemistry tests for protein, glucose, chloride 
levels, and viral PCR assay for cytomegalovirus, varicella zoster virus, and herpes 
simplex.  Lastly CSF samples were subjected to a diagnostic syphilis test by venereal 
disease research laboratory test (VDRL), fluorescent treponemal antibody absorption 
(FTA-ABS) and cysticercus antibodies tests. Each sample of CSF was subsequently 
biobanked using Xpert MTB/RIF analysis.  
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Figure 2:1  Summary flow chart of cohort design and patient selection. Initially 235 
TBM patients with a meningeal like illness were recruited, 31 patients were excluded, and 
the remainder were categorised, based on published diagnostic criteria, as TBM and non-
TBM. These patients were further divided into HIV positive and HIV negative. Both plasma 
and CSF samples were extracted from each HIV positive patient. Adapted from: (Patel et 
al., 2013). 
 
Clinical information recorded included: patient demographics, extent of symptoms, 
patients treated with either anti-tuberculous or steroid therapy, HIV status, history of TB, 
and history of TB contact. The test results obtained were used to categorize patients into 
three groups namely: definite TBM, probable-TBM and non-TBM based on standardized 
published diagnostic criteria (Thwaites et al., 2009). Hence, patients with positive CSF 
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M.tb culture and/or amplicor PCR were regarded as definite TBM, whilst patients that did 
not meet the standards for being definite TBM but were treated empirically with anti-TB 
drugs categorized as probable-TBM. Lastly, patients with a CSF M.tb. culture negative 
had an additional confirmatory alternate diagnosis and responded to therapy in the 
absence of anti-TB treatment were classified as non-TBM.  
 
For the purposes of this study all 20 (n=40) chronically infected, antiretroviral therapy 
(ART) naïve study participants were made available. Out of 20, 17 were defined as the 
TBM group, and 3 as the non-TBM control group. Each patient had a matched plasma 
and CSF sample recorded by a respective patient identification (PID). All together 17 TBM 
(n=34 samples) and 3 non-TBM (n=6 samples) participants, making a total of 20 PID’s 
(n=40 samples) were analysed (Figure 2:1). 
 
2.1.1. Baseline Demographic and Clinical Characteristics  
 
 
The demographic data for each study participant recorded at baseline included the 
median age and sex percentage (%) male (Table 2:1). In the TBM group the median age 
was 28 with an interquartile range [IQR] of 20 – 40 years, with 53% (majority) of study 
participants being males. The median age of the non-TBM group was 34 [IQR, 29-38] 
with majority female (66%).  
 
The baseline clinical data shows a median plasma CD4+ count of 117 cells/µl [IQR, 14 – 
677] and 113 cells/µl [IQR, 36 – 532] for the TBM and non-TBM groups is respectively 
(Table 2:1). Whilst, the median lymphocyte count in the CSF were 6 cells/µl [IQR, 2 – 
122] and 2 cells/µl [IQR, 0.24 – 6] for the TBM and non-TBM groups respectively. 
Comparing plasma viral loads, the TBM median viral load was 390 650 copies/ml [IQR, 
289 217 – 1 710 603] which was higher than the non-TBM group with a median plasma 
viral load of 102 025 copies/ml [IQR, 4317 – 213 260]. Consistent with a previous report 
(Morris et al., 1998), the median CSF viral loads of the TBM group was significantly higher 
630 291 copies/ml [IQR, 8133 – 10 000 000] compared to the non-TBM group 10 631 
copies/ml [IQR, 5109 – 14 230])(p = 0.020).  
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Table 2:1 Comparison of Demographic and Clinical Characteristics of study 
participants from TBM and Non-TBM groups 
 
Characteristics TBM Non-TBM P – value 
 
 
Demographic 
No. of study participants  17 3 N/A 
Sex % male 53% 33% 0.006# 
Median Age (IQR) years 28  
(20 – 40) 
34  
(29 – 38) 
0.221* 
 
 
 
 
 
 
Clinical 
Median CD4 count (IQR) 
cells/µl in Plasma  
117 
(14 – 677) 
113 
(36 – 532) 
0.695* 
Median lymphocyte count 
(IQR) cells/µl in CSF 
6 
(2 – 112) 
2 
(0.24 – 6) 
0.112* 
Median Plasma Viral Load 
(IQR) copies/ml  
390 650 
(289217 –  
1 710 603) 
102 025 
(4317 – 
213 260) 
0.169* 
Median CSF Viral Load 
(IQR) copies/ml 
630 291 
(8133 –  
10 000 000) 
10 631 
(5109 –  
14 230) 
0.020* 
 
N/A: Not applicable. IQR: Interquartile range. Significant differences between the groups are shown in 
bold P values 
#Fisher's exact test 
*Kruskal–Wallis test 
 
2.2.  Ethics  
 
Ethical clearance was obtained from the Biomedical Research Ethics Committee of the 
University of KwaZulu-Natal (Reference: BE201/18). Patient identifiers were removed 
and written informed consent was obtained from the study participants. The patients 
remained anonymous and recorded using patient ID (PID). The study was carried out in 
the HIV Pathogenesis Programme (HPP) Department at the University of KwaZulu-
Natal's Nelson R. Mandela School of Medicine Campus.  
 
2.3. RNA Extraction  
 
Viral RNA was extracted from CSF and plasma samples obtained from TBM and non-
TBM patients using QIAmp viral RNA Mini kit (Qiagen Inc., Valencia, CA, USA) as per 
manufacturer’s instructions. Briefly, 140 µl of either CSF or plasma sample was added in 
560 µl of Buffer AVL (viral lysis buffer) containing carrier RNA and incubated at room 
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temperature for 10 minutes to ensure complete lysis. To this lysate, 560 µl of ethanol was 
added to precipitate nucleic acids and enhance efficiency of viral RNA binding to the silica 
gel membrane of the QIAamp Mini column in the subsequent step. Approximately 630 µl 
of the solution made in the prior step was applied directly to the silica gel membrane of 
the QIAamp Mini column that was inserted in a 2ml collection tube, centrifuged at 8000 
rpm for 1 minute and the filtrate together with the collection tube was discarded. This step 
was repeated twice to make sure that all the solution containing viral RNA passed through 
the silica gel membrane to the QIAamp Mini column. A volume of 500 µl of wash Buffer 
AW1 was added to the QIAamp Mini column to wash away the debris or contaminants in 
the QIAamp Mini column, this was centrifuged at 8000 rpm for 1 minute, and the filtrate 
together with the collection tube was discarded. Washing was repeated using 500 µl of 
wash Buffer AW2, the QIAamp Mini column containing the sample was centrifuged at 
14000 rpm for 3 minutes, the filtrate together with the collection tube was discarded. 
Lastly, the column containing viral RNA bound to its silica gel membrane was placed in a 
sterile 1.5 ml tube, 50 µl of elution Buffer AVE was added directly to the silica membrane 
without touching the silica membrane or wetting the rim and incubated at room 
temperature for 1 minute.  The column was then centrifuged at 8000 rpm for 1 minute 
resulting in a sample of pure viral RNA being eluted into a sterile 1.5ml tube. Extracted 
viral RNA samples from CSF and plasma were stored at -20oC until use. 
 
2.4. cDNA Synthesis  
 
The extracted viral RNA was reverse transcribed to complementary DNA (cDNA) using 
SuperScript IV Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA), as per 
manufacturer’s instructions. Briefly, a reaction mixture to anneal the primer to the 
template viral RNA was prepared in a 13 µl reaction volume, made of 5 µl  of either 
extracted CSF or plasma RNA, 0.2 mM dNTP mix, 0.1 µM gene specific primer (TatR1) 
and 6 µl of Diethyl pyrocarbonate (DPEC) water. The reaction mixture was incubated at 
65oC for 5 minutes. Subsequently a 7 µl reverse transcription mix was prepared  by mixing 
1X SSIV buffer, 5 mM DTT, 2 U/µl RNaseOUT recombinant RNase inhibitor and 10U/µl 
SuperScript IV reverse transcriptase. Next the reverse transcription mix was added to the 
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annealed primer.  This mixture was then incubated at 50oC for 10 minutes and the 
reaction terminated at 85oC for 5 min. Extracted reverse transcribed samples from CSF 
and plasma was stored at -20oC until use. 
 
2.5. Polymerase chain reaction (PCR) 
 
The 216 nucleotides of tat exon 1 were amplified through two rounds of polymerase chain 
reaction (PCR), known as nested PCR using the Platinum ® Taq DNA Polymerase High 
Fidelity PCR kit (Thermo Fisher Scientific, Boston, MA, USA). The first round of PCR was 
carried out in a 25μl reaction volume containing 1X High Fidelity PCR Buffer, 2.0 mM 
MgSO4, 0.2 µM dNTP mix, 0.2 µM forward primer (Tat F1 5’-CATTTCAGAATTGGG-3’), 
0.2 µM reverse primer (Tat R1 5′-TTGCTATTATTATTGCTAC-3′)(Cowley et al., 2011) 
and 1 U/rxn Platinum® Taq DNA Polymerase High Fidelity enzyme, to this solution a 2.5 
µl cDNA template was added and DPEC water was used to make up a final reaction 
volume of 25 µl. The second round of PCR (Nested PCR) was performed in a 25 μl 
reaction using 0.2 µM forward TatF3 (5′-AGACGACAGAGAAGAGCAAG-3′) and reverse 
TatR3 (5′-CATTACTATTTTGTACTTACTGC -3′) primers (Cowley et al., 2011). To this 
solution a 2 µl volume of DNA from the first round of PCR was added and DPEC water 
was used to make up a final reaction volume of 25 µl. Both rounds of PCR were carried 
out under the following thermalcycler conditions: denaturation at 94°C for 2 minutes; 30 
cycles at 94°C for 15 seconds; 50°C for 30 seconds and 68°C for 1 minute; and a final 
extension step at 68 °C for 5 minutes. The presence of PCR products was verified on a 
2% agarose gel and stained with GelRed and visualized under ultraviolet light. 
 
Subsequently PCR products with a band size of approximately 255 bp were subjected to 
a PCR clean up using QIAquick PCR Purification Kit (Qiagen Inc., Valencia, CA, USA) as 
per manufactures instructions. Briefly, 100 µl of Buffer PB was added to 20 µl of remaining 
PCR product, the mixture was transferred into a QIAquick spin column collection tube 
and centrifuged for 1 minute at 13 000 rpm to allow for efficient binding of the DNA to the 
membrane. Afterwards, the filtrate in the collection tube was discarded and 750 µl of 
Wash Buffer PE was added to the spin column. The sample was then centrifuged for 1 
minute at 13 000 rpm to remove any remaining contaminants. The DNA was eluted from 
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the spin column into a sterile 1.5ml tube using 10mM EB buffer (pH 8.5). The yield of the 
purified DNA was quantified using the NanoDrop™ 2000 spectrophotometer (Thermo 
Scientific, Delaware, USA) and stored at -20 °C.  
 
2.6. DNA Sequencing and Phylogenetic Analysis 
 
Nucleotide sequences were obtained by direct sequencing of the HIV-1 purified tat 
amplicons. The DNA sequencing was performed in a 96 well plate (Applied Biosystems) 
using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific, 
Boston, MA, USA) as per manufacturer’s instructions. Briefly a 10 µl sequencing reaction 
was separately prepared for each nested PCR primer (TatF3 and TatR3). Each 
sequencing reaction contained 3.2 µM primer, 1X Sequencing Buffer, 0.4 µl of Big Dye 
Terminator v3.1 Ready Reaction Mix, 20 ng of purified PCR products and DPEC water to 
make a final volume of 10 µl. The sequencing reactions were then subjected to an initial 
denaturation at 96°C for 1 minute; followed by 25 cycles of denaturation at 96°C for 10 
seconds, annealing at 50°C for 10 seconds, and extension at 60°C for 4 minutes.  
 
Following the cycle-sequencing reaction, sequences underwent a sequencing reaction 
clean up. Briefly 1ul of 125 mM ethylenediaminetetraacetic acid (EDTA) (pH 8.0) was 
added into each well, followed by the addition of a 26 µl solution made up of; 1ul of sodium 
acetate (NaOAc) (3M, pH5.2), and 25 µl of ice cold 100% ethanol (previously stored at -
20oC) to precipitate DNA sequences and this was followed by centrifugation at 4000 rpm 
for 20 minutes (Eppendorf centrifuge 5810R, Merck, Germany). The supernatants were 
removed by inverting the plate and centrifuging at 880 rpm for 1 minute which was 
followed by the addition of freshly made ice cold 70% ethanol to each well. The plate was 
then centrifuged again at 4000 rpm for 5 minutes and inverted 880 rpm for 1 minute to 
remove the supernatant. Lastly, the sequencing reactions were then dried at 50°C for 5 
minutes and stored at -20oC until analyzed using the ABI 3130xl Genetic Analyzer 
(Applied Biosystems). To run plates on the ABI 3130xl Genetic Analyzer, sequencing 
products were re-suspended in 10μl of highly deionized formamide (HiDi-formamide), 
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mixed and denatured at 95ºC for 3 minutes and cooled to 4ºC for 3 minutes in a 
thermalcycler. 
 
 
Figure 2:2  Overview of molecular methods use to amplify and sequence HIV-1 tat. 
(1) Viral RNA was extracted from all plasma and CSF samples. (2) Extracted RNA was 
reverse transcribed into cDNA. (3) All cDNA products were amplified using two rounds 
(nested) of PCR. (4) Amplified DNA was run on a gel to confirm size. (5) All tat amplicons 
were subjected to Sanger sequencing. (5) Sanger sequences were analysed, and a 
phylogenetic tree was drawn. 
 
The tat sequences were edited and analyzed using the Sequencher 5.1 software (Gene 
Codes Corporation, Ann Arbor, USA). Sequences were then aligned to a tat subtype C 
consensus sequence (GenBank accession No. EU293450.1) from the Los Alamos HIV 
Sequence Database (https://www.hiv.lanl.gov/) using the Clustal W (Thompson et al., 
1994) multiple-sequence alignment program. Subsequently, a neighbor-joining 
phylogenetic tree (Saitou and Nei, 1987)  was then generated using the Geneious 
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software v10.2.3 (Biomatters, Ltd., Auckland, New Zealand).  A diversity analysis based 
on divergence was done using the codon-aligned nucleotide sequences with MEGA X 
(Kumar et al., 2018). The model of substitution used was nucleotide and the method used 
was p-distance. The codon-aligned nucleotide sequences of tat exon-1 variants were then 
translated into amino acid sequences using the online software Gene Cutter 
(www.hiv.lanl.gov) and visualized using BioEdit v.7.0.9. 8 (Hall, 1999) for further analysis. 
A Tat amino acid sequence logo was generated by using Weblogo 3.1 
(http://weblogo.threeplusone.com). Subsequently a Viral Epidemiologic Signature Pattern 
Analysis (VESPA) (www.hiv.lanl.gov) was carried out to determine the presence of 
signature amino acid substitutions. 
 
2.7. Cloning into pTargeT™ Mammalian Expression Vector System 
 
 
Out of the 38 PCR products generated (32 TBM and 6 non-TBM), twelve sequences were 
chosen for downstream functional assays. Hence one representative sequence was 
chosen from 10 patients (except X205 where both plasma and CSF derived Tat were 
selected). Therefore, a total of 12 samples with key mutations reported to affect Tat 
activity were selected for cloning. These 12 PCR products were cloned into a T-tailed 
vector pTargeT™ expression plasmid (Promega Corporation, Madison, WI) according to 
the manufacturer's instructions. In the pTargeT™ expression vector, the HIV-1 tat exon 1 
target sequence is under the control of T7 and CMV promoter.  
 
In the ligation reaction, up to 2 µl of the nested PCR product was added into the pTargeT 
vector in a standard reaction volume of 10 µl. For the positive control, 2 µl of control DNA 
was ligated into pTargeT vector, whilst the background control contained an empty 
pTargeT vector with no insert. Ligation reaction tubes were incubated overnight at 4oC. 
Transformation of each sample was performed by adding 2 µl of each ligation reaction 
into a 1.5ml tube containing 50 µl of JM109 high efficiency competent cells (Promega 
Corporation, Madison, WI) for each sample, whilst the control tubes contained 100 µl of 
JM109 cells. Tubes were subjected to heat shock for 50 seconds at 42oC in a water bath. 
A total volume of 950 µl and 900 µl of SOC medium was added into the sample tube and 
31 
 
control tube respectively to reach a final volume of 1ml. Tubes were then incubated for 1 
hour and 30 minutes at 37oC with shaking at 150 rpm. After which 100 µl of each 
transformation reaction were plated on ampicillin agar plates and incubated overnight at 
37oC. Blue/white screening was used for confirmation of tat clones using X-gal (Thermo 
Fisher Scientific, Boston, MA, USA).  
 
Colony PCR was employed for screening clones generated. Briefly, colonies grown on 
ampicillin plates were picked and boiled at 95oC for 10 minutes. Afterwards each clone 
was amplified using nested PCR as previously described. The presence of PCR products 
was verified on a 2% agarose gel and stained with GelRed and visualized under ultraviolet 
light.  All positive clones with a band size of approximately 255bp, were inoculated into a 
3ml of Lysogeny broth (LB), containing 3 µl of ampicillin.  The culture was then grown at 
37oC in a 230rpm shaking incubator (Infors HT, Bottmingen, Switzerland) for 16 hours. 
Purified plasmid DNA were extracted using the GeneJET Plasmid Miniprep Kit (Thermo 
Fisher Scientific, Boston, MA, USA). All purified plasmid DNA were subjected to a 
restriction digest using EcoRI (New England Biolabs, Hitchin, UK) at 37oC for 1 hour. The 
confirmation of each tat insert (approximately 255bp) that was successfully cut from 
plasmid (approximately 5670bp) was verified on a 1% agarose gel. All plasmid DNA with 
a confirmed tat insert after restriction were sequenced using Sanger sequencing as 
previously described. This was followed by sequence analysis to determine if the clonal 
sequence matched the bulk sequence previously amplified. 
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Figure 2:3 Summary outline of cloning procedure. (1) PCR purified tat amplicons with 
interesting mutations were ligated into a pTargeT vector with T4 DNA ligase, creating a 
recombinant plasmid. (2) Recombinant plasmids were heat shocked into JM109 
competent cells. (3) Transformed JM109 cells were grown on ampicillin agar. (4) The 
correct plasmid was chosen via colony screening methods such as, blue/white screening, 
restriction digestion, colony PCR and Sanger sequencing to confirm the insert of tat. 
(Source: Adapted from http://www.khanacademy.org). 
 
Once the insert containing specific mutations were confirmed, plasmid DNA was 
propagated in 100ml of LB broth containing 100µg/ml ampicillin and incubated overnight 
at 37oC in a shaking incubator (Infors HT, Bottmingen, Switzerland). Plasmid DNA was 
then purified using the QIAfilter Plasmid Maxi Kit (Qiagen Inc., Valencia, CA, USA) and 
concentrations of approximately 1.5µg were quantified using a NanoDrop 
spectrophotometer (Thermo Scientific, Delaware, USA) and stored in a -80°C ultrafreezer 
until use.    
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2.8. Tat Transactivation Assay  
 
To assess the functional diversity of selected HIV-1 tat variants, a Tat Transactivation 
Assay was performed. This assay is divided into 3 major parts: culturing the cells, 
transfecting pTargeT tat variants into TZM-bl cells and measuring the luminescence of 
Tat variants with a luciferase assay. The TZM-bl cells were chosen as host cells for 
transfection because the cell line contains an integrated reporter gene for firefly luciferase 
(luc) driven by the LTR promoter. Therefore, the cells had grown relative to the attenuation 
of the viral tat and luciferase activity was directly proportional to transactivation activity of 
the Tat mutant.  
 
2.8.1 Maintenance and Preparation of TZM-bl cells 
 
As previously mentioned the transactivation assay was carried out using TZM-bl cells 
(also called JC53BL-13) obtained from the NIH AIDS Research and Reference Reagent 
Program (Cat. No. 8129). The TZM-bl cells are adherent HeLa cell derivatives that 
express reporter genes; galactosidase (LacZ) and firefly luciferase (luc) under the control 
of a subtype B HIV-1 LTR (Sarzotti-Kelsoe et al., 2014). The cells were cultured in a 
growth medium (GM) consisting of Dulbecco modified Eagle medium (DMEM) (Gibco 
BRL, Life Technologies, Cergy Pontoise, France) supplemented with 50ml of 10% heat 
inactivated fetal bovine serum (FBS) (Gibco BRL, Life Technologies, Cergy Pontoise, 
France), 125 ug/ml Gentamicin (Sigma–Aldrich, St. Louis, MO, USA) and 10 mM of 
HEPES (Gibco BRL, Life Technologies, Cergy Pontoise, France).  
 
To plate the cells, a 1ml vial of cells previously stored in liquid nitrogen freezer were 
thawed by swirling the vial in a 37oC water bath for 5 minutes. Thereafter the thawed cells 
were transferred into a 50 ml conical tube supplemented with 30 ml of pre-warmed GM. 
The 50ml tube containing the cells and GM were centrifuged for 10 minutes at 1000 rpm 
(Eppendorf centrifuge 5810R, Merck, Germany). The supernatant was discarded, and 
cells were suspended in 15 ml of fresh GM, transferred into a T-75 culture flask and 
incubated for 48 hours at 37oC. After 48 hours of incubation, culture flask containing cells 
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were then viewed on the Zoe® fluorescent imager (Bio-Rad) to assess for a 90-100% 
confluency. Thereafter cells were split by decanting the supernatant and rinsing the 
monolayers with 5 ml of sterile Phosphate-Buffered Saline (PBS) (pH7.2) (GIBCO 
Laboratories, Grand Island, NY). Subsequently cells were trypsonized with 3 ml of 0.25% 
Trypsin-EDTA (GIBCO BRL, Life Technologies, Cergy Pontoise, France). This was 
followed by incubation at room temperature for 30 seconds. After which the trypsin 
solution was removed, and cells were further incubated at 37oC in 5% CO2 for 4 minutes. 
The flasks were then suspended with 10 ml of GM and seeded in new T-75 culture flasks 
with approximately 1 x 106 cells in 10 ml GM. The flasks were then incubated at 37oC in 
a 5% CO2 and 95% air environment.  
 
To determine the number of cells per ml of GM, flasks containing cells that were 90-100% 
confluent were split as previously mentioned and 10 µl of cells were thoroughly mixed 
with 10 µl of Tryphan blue (BIO-RAD Laboratories, Hercules, CA) and counted using the 
TC20™ Automated Cell Counter (BIO-RAD Laboratories, Hercules, CA). 
 
A 24 well plate was used to plate 4 x 104 cells into each well (supplemented with 500 µl 
of GM) that would be required for transfection. Thereafter T-75 flasks with remaining cells 
were maintained daily until a passage number of 15 was reached. After which time a new 
viral of stored TZM-bl cells were used.  
 
2.8.1 Transfection using Lipofectamine 2000 
 
 
A 24 well plate containing approximately 4 x 104 cells per well at a 70 – 80% confluency 
were prepared as previously explained. Briefly, two 2-ml Eppendorf tubes were prepared 
per each well, 1 tube to contain 1.5 µg of plasmid DNA and 250 µl of OPTI-MEM I 
reduced-serum medium (Gibco-BRL, Paisley, UK) and the other with 10 µl of 
Lipofectamine 2000 (Invitrogen, CA, USA) and 250 µl of OPTI-MEM I reduced-serum 
medium (Gibco-BRL, Paisley, UK). After 5 minutes of incubation at room temperature 
both tubes were combined to form a Lipofectamine 2000 transfection complex, followed 
by incubation for 25 minutes at room temperature. During this interval, the 24-well plate 
containing cells were prepared by removal of old GM and each well was replenished with 
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1.5ml of fresh GM. After the 25 minute incubation the Lipofectamine 2000 transfection 
complex was then added to each corresponding well and rocked gently back and forth to 
distribute the Lipofectamine. Each sample was done in triplicate. A patient derived Tat 
sample (PID A219) that was highly similar to the Tat subtype C consensus sequence 
(96%) was used as the consensus C control, whilst a pTargeT vector without any tat insert 
was used as a negative control. Both controls were similarly transfected into TZM-bl cells.  
Each plate was then incubated at 37oC in a 5% CO2 and 95% air environment for 24 
hours. Following a 24 hour incubation, 1.5 ml of supernatant was removed from each well 
and replenished with 2 ml of pre-warmed GM and incubated at 37oC in a 5% CO2 and 
95% air environment for an additional 24 hours. 
 
2.8.2 Luciferase Assay using Bright-Glo 
 
After 24 hours, approximately 1.9 ml of supernatant was removed from each well leaving 
a 100 µl layer of supernatant to cover the cells in each well. The cells were lysed with 100 
µl of Bright-Glo™ Luciferase Assay System (Promega, Madison, WI, USA) and were 
incubated at room temperature for 2 min, in the dark. Following incubation, the contents 
of the pate were mixed twice by pipetting, thereafter 150 µl of the lysate was transferred 
to corresponding wells of a 96 well black solid bottom microplate (Greiner Bio‐One, 
Monroe, NC).  
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Figure 2:4 Summary outline of Tat transactivation assay procedures. (Source: 
Adapted from https://www.thermofisher.com) 
 
The luciferase activity was determined using a VICTOR Nivo Multimode Microplate 
Reader (Perkin-Elmer Life Sciences, Shelton, CT) and the output data was expressed as 
relative light units (RLUs). Firefly luciferase values measured in relative luminescence 
units (RLU) were normalized against a cell control containing TZM-bl cells only. The 
relative fold change for each sample were calculated relative to the consensus. A 
Student’s t test was performed on each patient derived Tat against the consensus C Tat. 
The Pearson correlation coefficient and linear regression was used to measure the 
correlation between Tat transactivation and patients’ viral load and lymphocyte counts.  
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3. Results 
 
 
3.1. Phylogenetic Analysis Reveals High Genetic Diversity of Tat Exon-1  
 
Initially a total of 20 PID’s (n=40 [20 plasma and 20 CSF] samples) were chosen, however 
we were unable to amplify HIV-1 tat from the CSF and plasma of 1 TBM patient. 
Therefore, a phylogenetic tree was constructed using 38 HIV-1 tat sequences obtained 
from 19 patients (16 TBM and 3 non-TBM). For each patient ID (PID), we used one tat 
sequence composed of 216 nucleotides from each compartment. The tree was rooted to 
a subtype c tat consensus (GenBank accession No. EU293450.1). 
 
Our data demonstrated that matched plasma and CSF tat sequences from each patient 
clustered together. This indicates they were isolated from the same patient, more so there 
were no cross-contamination between PID’s (Figure 3:1). Intermingling between paired 
clusters of the TBM and non-TBM patients were observed and no distinct 
compartmentalization was seen within these two groups, which could be due to a small 
sample size of the non-TBM group. Interestingly PID A129 (non-TBM) paired closely with 
the subtype C tat consensus, suggesting that viruses from this PID were closely related 
to the consensus sequence. 
 
Although three major clusters were formed, the non-TBM patients all grouped within one 
cluster whilst the TBM were dispersed. Within each cluster, each subpopulation showed 
variation in the tat quasispecies (Figure 3:1). Distinct differences in branch lengths 
between CSF and plasma sequences of PID’s: A96, A105, X215, X205, B98 (TBM) and 
X235 (non-TBM) were observed, suggesting diversity differences within the two 
compartments. Conversely, some patients had little or almost no differences between 
their respective plasma and CSF sequences, including X201, A104, X195, X223 (TBM), 
A129 and X229 (non-TBM), suggesting that the same viral strains were dominant in the 
two compartments. 
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Figure 3:1 Neighbor joining phylogenetic tree representing 19 matched plasma and 
CSF derived tat sequences.  All sequences in the tree were 216 nucleotides in length. 
The tree was rooted to a subtype C tat consensus sequence (GenBank accession No. 
EU293450.1), and each plasma sequence paired with its respective CSF sequence from 
the same patient. All TBM patients were marked in black whilst all non-TBM patients 
marked in blue.  There was no cross contamination between sequences. All sequences 
were related to the subtype C consensus and two clusters formed. A scale of 0.02 
represents 20% nucleotide differences between sequences.  
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3.2. Genetic diversity analysis 
 
In order to assess tat nucleotide diversity within compartments of TBM and non-TBM 
patients as observed in Figure 3:1, nucleotide alignments were generated and used to 
calculate both interpatient and intrapatient genetic diversity analyses. This would allow 
for a more accurate measure of the displayed relationships in the phylogenetic tree. 
Average pairwise distance (APD) is a statistic tool commonly used in published methods 
of phylogenetic analysis. P-distance is a measure of APD and defined as the number of 
nucleotide differences between two sequences/total nucleotide sequences (s/nt). In most 
HIV-1 diversity studies, the p-distance determinations are relatively small (<0.03) (Kumar 
and Nei, 2000).  
 
3.2.1 Interpatient P-distance Analysis 
 
The interpatient p-distance analysis calculated the nucleotide divergence, as a measure 
of the genetic distance between plasma and CSF sequences in each PID. In this analysis 
we hypothesized that TBM would drive a high viral diversity. To perform this analysis, 
aligned tat sequences were separated into two groups (TBM and non-TBM) using MEGA 
X. The average mean distance (s/nt) for TBM and non-TBM patients were 0.003 and 
0.002 respectively. As seen in Figure 3:2, the TBM group had a greater amount of 
diversity compared to the non-TBM group although this was not significant. The highest 
diversity was seen in PID X205 and A96 when comparing their CSF sequence to their 
respective plasma sequence. Furthermore A105, X215 and B98 were all represented with 
the same p-distance and this was comparable to X235 of the non-TBM group.  
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Figure 3:2: Interpatient diversity analysis of TBM and non-TBM study participants. 
The above plot shows the mean and SEM of both the TBM and non-TBM groups. Each 
dot represents the distance whereby the plasma and CSF sequence of each PID being 
compared are different. It is obtained by dividing the number of nucleotide differences by 
the total number of nucleotides compared. 
 
 
Whilst majority of the participants had a p-distance of 0.00 this does not regard them as 
having no diversity – rather there is no difference in the p-distance between their plasma 
and CSF sequence. Overall there was no significant differences in tat diversity between 
TBM and non-TBM participants.  
 
3.2.2 Intrapatient P-distance Analysis 
 
An intrapatient p-distance analysis was conducted to assess the difference between the 
plasma and CSF tat sequences within TBM coinfected patients. We hypothesized that 
the higher viral load in the CSF compartment would result in a higher CSF tat diversity 
compared to plasma. Briefly, aligned tat sequences were put into groups (plasma and 
CSF) and compared to a Tat consensus C sequence (GenBank accession No. 
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EU293450.1) using MEGA X. This comparison would indicate; how much tat has evolved 
from the transmitter consensus like strain and whether the CSF compartment has a higher 
viral tat diversity than the plasma compartment.  Whilst the mean p-distance seen in the 
CSF compartment is slightly higher than the plasma (p = ns) (Figure 3:3), the calculated 
overall average mean distance (s/nt) generated for plasma and CSF from TBM patients 
had a negligible difference of 0.059 and 0.062 respectively.   
 
                    
 
Figure 3:3: Intrapatient diversity analysis of plasma and CSF derived tat sequences 
from TBM study participants. The above plot shows the mean and SEM of both the 
plasma sequences (red) and CSF sequences (blue). Each dot represents the distance 
whereby the plasma and CSF sequences are different to a consensus C sequence. It is 
obtained by dividing the number of nucleotide differences by the total number of 
nucleotides compared. 
 
Overall there was no significant differences in diversity between plasma and CSF derived 
tat sequences in patients with TBM. Since TBM viruses are the focus of this study, all 
further analyses will be based on their respective plasma and CSF HIV-1 sequences.  
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3.3. Amino acid analysis of Tat exon-1 variants 
 
A total of 38 HIV-1C tat sequences (obtained from 19 CSF and 19 plasma samples) were 
translated to amino acids and aligned for analysis. As previously mentioned the HIV-1C 
Tat protein structure is divided into five domains encoded by the first exon. Domain I is 
composed of amino acids (aa): 1–21 also known as the acidic domain. Domain II, aa: 21–
37 known as the cysteine-rich domain. Domain III (aa: 38–48) is the core domain, Domain 
IV (aa: 49–57; basic domain) and Domain V (aa: 58–72) is the glutamine domain. Amino 
acids 1–48 are efficient for Tat transactivation. Whilst aa: 49–57 is the RNA binding 
domain (RBD) (Figure 1:4).  
 
 
3.3.1 Conservation of Tat amino acid sequences  
 
The Tat amino acid logo generated, graphically represents the patterns within a multiple 
sequence alignment (Figure 3:4). The height of each amino acid indicates frequency of 
the amino acid at that position (Crooks et al., 2004).  
 
The acidic domain of Tat was proline rich and relatively well conserved, with two major 
variable positions 7 and 19 (Figure 3:4). In comparison the cysteine region of Tat seemed 
highly diverse with variable positions 23, 24 and 29. Consistent with the previous studies 
the 6 cysteine residues reported in HIV-1C remained well conserved (Rao et al., 2013). 
Additionally, we identified the previously reported di-cysteine motif C30C31 in our cohort 
(Figure 3:4), however S31 was more prevalent as commonly seen in subtype C variants 
(Ranga et al., 2004, Wong et al., 2010, Campbell et al., 2011).  
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Figure 3:4 : Tat amino acid sequence logo. All 38 Tat sequences were aligned to create 
a Weblogo. The x-axis shows the position of each amino acid, y-axis shows the frequency 
of amino acids measured in bits. The five regions of tat exon 1 are highlighted: An N-
terminal acidic domain comprising the first 21 amino acids of Tat, with a highly conserved 
Tryptophan 11 (W11), a cysteine-rich domain with six well conserved cysteine amino 
acids at positions in subtype C, the core domain has a conserved Phenylalanine (F38) 
and amino acid sequence LGISYG. The basic domain made of amino acids 49–57 and 
has a well conserved RKKRRQRR basic amino acid sequence. Lastly the glutamine-rich 
domain with high sequence variation. 
 
The most important functional domains in Tat are the core and basic domains, with 
conserved motifs; LGISYG (43 – 48) and RKKRRQRR (49 – 56). The core domain motif 
remained 83% conserved with only a S46Y substitution in 3 samples (Figure 3:4). Whilst 
the basic domain motif was only 63% conserved and many low frequency mutations 
including R52W, R53S, R53K and Q54R were observed (Figure 3:4). The extent of this 
variability seen in Tat from HIV-1 chronically infected patients who have TBM will be 
further analyzed. Lastly the glutamine domain had the most sequence variation (80%), 
with many non-conservative mutations (Campbell et al., 2004). 
 
A subtype C amino acid consensus was created from the Tat amino acid logo generated 
and used a means of comparison to identify patient derived Tat mutations (Figure 3:4). It 
should be noted that our consensus contained a 21A, whilst the wildtype amino acid in 
Tat variants is a 21P (Rossenkhan et al., 2013). 
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3.3.2 Mutations in Tat  
 
A multiple sequence alignment was performed to determine the presence of specific 
residues that distinguish CNS and plasma Tat proteins (Figure 3:5). Whilst no major 
difference between CSF and plasma derived Tat were observed, the presence of amino 
acid substitutions within domains previously reported to affect Tat function, were 
observed in both compartments and assessed.  
 
Mutations previously described to significantly affect LTR-mediated transcriptional activity 
were observed in all domains of Tat. A list of 10 Tat mutations collated from existing 
literature (Table 3:1) was used as a reference to identify mutations in Tat that have been 
associated with an increase or decrease in LTR-mediated transcriptional activity. Eight 
out of 10 Tat sequences had mutations known to be associated with a detrimental Tat 
activity were detected (Table 3:1 and Figure 3:5). These included: V4I, P21A, K24S, 
S31C, S46Y, R52W, P59S and D64N which will be subsequently discussed. The 
remaining 2 of the 10 Tat sequences had mutations: H29R and S57R, which were 
reported to be associated with enhancing Tat activity.  
 
Mutations in TBM patients with a detrimental impact on LTR activation (Figure 3:5): 
 
(i) Within the acidic domain, 48% of amino acids were highly conserved, whilst 52% 
had sequence variation. Although there were contradictory reports regarding the 
importance of the acidic domain, with one study suggesting that high sequence 
variation within this domain does not impact Tat activity (Li et al., 2012). Whilst 
another showing the mutations V4I and P21A significantly altered the activity of 
Tat (Rossenkhan et al., 2013). Our data demonstrate that mutations V4I as seen 
in 5 of 16 TBM patients and P21A as seen in 7 of 16 TBM patients have been 
associated with a lower Tat transactivation activity, thus confirming the latter study 
(Rossenkhan et al., 2013). Furthermore, the acidic domain is a proline-rich domain 
and many low frequency mutations at proline residues namely; P2L, P6T and 
P10S were observed in this cohort. However, mutations in proline residues other 
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than P21A affecting Tat function is still unknown. Therefore, the data from this 
study warrants the further characterization of mutations: P2L, P6T and P10S. 
 
(ii) The cysteine domain had 56% of sequence variation in this cohort. Although high 
sequence variation in this domain is uncommon, all 6 cysteine residues linked to 
Tat function remained highly conserved. In addition the C31S and dicystine motif 
C30C31 was seen in 84% and 16% respectively – although the C31S mutation is 
most frequently observed in subtype C (Rao et al., 2013). In addition, the 
functional capability of C31S versus C31C is still unclear. Position 24 was one of 
the most highly diverse amino acid positions and mutation K24S, previously 
reported with altered Tat activity was observed in PID A105 (Figure 3:4) 
(Rossenkhan et al., 2013).  
 
(iii) Whilst the core domain of Tat are reportedly highly conserved (Jeang, 1996), 27% 
diversity was observed in this region (Figure 3:4). At position 46, 13% of plasma 
sequences and 6% of CSF sequences had the S46Y substitution. Position 46S is 
a site of phosphorylation and amino acid substitutions at this site is associated 
with reduced transactivation (Cowley et al., 2011). In addition 19% of patients had 
a T40K mutation, which was identified as a signature residue for Indian HIV-1C 
(Neogi et al., 2012). 
 
(iv) The basic domain is responsible for Tat binding to the TAR element. While this 
region is reportedly well conserved – 44% of sequence variation was observed in 
our cohort. Although mutations that abolish the Tat-TAR interaction have not yet 
been reported. An R52W mutation was observed in PID 68 and this mutation was 
previously associated with high attenuation of the viral transactivation activity 
(Sivakumaran et al., 2007). In addition, unreported mutations including R53S 
could allow for a greater attenuation of Tat activity and needs to be further studied. 
The mutations in this domain warrants bind affinity assays such as electrophoretic 
mobility shift assay (EMSA) in order to determine their impact on Tat binding to 
the TAR element.  
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(v) Lastly, the glutamine domain had fairly high sequence variation with only 3 
positions being fully conserved. This is consistent with previous reports suggesting 
that the glutamine domain has the greatest degree of variability within Tat (Li et 
al., 2012). With such high sequence variation, it is unclear which residues correlate 
to impaired Tat activity. However the P59S mutation observed in PID X233 was 
previously associated to decrease in LTR activity (Rossenkhan et al., 2013).  
 
Mutations in TBM patients with an enhancing effect on LTR activation (Figure 3:5); 
 
(i) Position 29 is highly variable within the cysteine domain. Mutation frequencies 
were as follows: H29K (31%), H29R (19%), H29Y (13%), H29S (13%), H29C (6%), 
and H29F (6%). Of all the amino acid substitutions seen in this position, only the 
H29R mutation has been reported to significantly upregulate LTR-luciferase 
expression (Rossenkhan et al., 2013).Therefore, the other mutations at this 
position necessitate the characterization of their impact on Tat activity. 
 
(ii) Position 57 in the basic domain had two low frequency mutations. Which included 
S57G and S57R which observed in 6% and 13% of matched plasma and CSF 
sequences respectively. Whilst the functional activity of the S57G mutation is not 
known, the S57R has been previously reported to enhance LTR transactivation 
activity (Endo-Munoz et al., 2005). These data suggest the need to characterize 
the function of S57G mutation.  
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Figure 3:5 Amino acid sequence alignment of subtype C consensus sequence and 
38 full length patient derived Tat sequences. Schematic presentation of the 71 amino 
acids within Tat exon 1: domain I (residues 1 to 21, acidic domain); domain II (residues 
22 to 37, cysteine domain); domain III (residues 38 to 48, core domain); domain IV 
(residues 49 –57, basic domain) and; domain V (residues 58–71, glutamine domain). All 
sequences are aligned to subtype C consensus in the first line of the alignment, the dots 
represent residues identical to the consensus. Outlined in red is all non-TBM study 
participants. 
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Table 3:1 Allele frequency of previously reported Tat mutations in the CSF and 
plasma compartments of all 16 TBM study participants. 
 
Functional Domain Mutations Allele Frequency (%) 
PLASMA CSF 
Acidic Domain V4I 31 31 
Acidic Domain P21A 43 43 
Cysteine-rich Domain K24S 6 6 
Cysteine-rich Domain H29R 25 19 
Cysteine-rich Domain S31C 18 18 
Core Domain S46Y 13 6 
Basic Domain R52W 6 6 
Basic Domain S57R 13 13 
Glutamine Rich Domain P59S 6 6 
Glutamine Rich Domain D64N - 6 
 
 
Additionally, a VESPA analysis to detect CNS signature residues was conducted on all 
16 TBM plasma and CSF sequences to determine the difference in viral signature 
patterns. Although no signature residues were found, a further codon by codon analysis 
showed that patients; A105, B98 and A96 harboured additional mutations in the CSF that 
were absent from the plasma compartment these include T20P, H29K and D64N 
respectively. The effect D64N mutation on transactivation activity of Tat, was 
subsequently assessed. 
 
3.4. Tat Transactivation activity   
 
 
To determine the impact of specific Tat variants on HIV-1 LTR transcription, a Tat 
Transactivation assay was carried out using TZM-bl cells as previously described (section 
2.8). Since the amino acids of reported mutations, were seen in almost equal proportions 
within plasma and CSF compartments (Figure 3:3, Table 3:1), one representative 
sequence was chosen from each study participant (except X205 where both plasma and 
CSF derived Tat were selected). The basis of this was to identify amino acid substitutions 
that allowed for altered transactivation abilities of Tat. Briefly patient derived Tat samples 
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containing reported mutations were selected. These Tat variants were compared to a 
patient derived Tat sequence (A129C) that highly represented (96%) the subtype C 
consensus sequence previously described with only 3 amino acids changes:  21P, 58T 
and 68L. Henceforth A129C will be referred to as the subtype C consensus. 
 
Overall two analyses were performed:  
 
(i) The relative change in LTR activity of patient derived Tat 
(ii) The relative change in LTR activity of a single polymorphism 
 
Within the patient derived Tat, heterogeneity was observed in the ability of CSF and 
plasma derived Tat variants to transactivate the LTR (Figure 3:6). The transactivation 
ability of Tat was determined by the relative change in LTR activity. Overall patient derived 
Tat from 5 patients (A130C, B98C, X195C, X205P and A111C) had significantly restricted 
capacity to transactivate the LTR. 
 
Patient A130C with mutation V4I had significantly downregulated LTR activity by 37% (± 
6%) relative to the subtype C consensus (p = 0.01). A previous report showed that the 
V4I mutation had significantly downregulated LTR activity through site directed 
mutagenesis (Rossenkhan et al., 2013). In our study, we did not perform site directed 
mutagenesis, however the A130C patient derived Tat that contained other mutations 
together with the V4I mutation showed a decreased LTR activity. In addition the V4I 
mutation coupled with P21A  as seen in X195C resulted in only a 34% (± 7%) reduction 
in Tat activity (p = 0.02), although the dual effort of both mutations has not been previously 
reported, the single effect of V4I and P21A is known to lower LTR activation (Rossenkhan 
et al., 2013). Another double mutation P21A and S46Y seen in patient B98C significantly, 
decreased LTR activity by 46% (± 6%) (p = 0.007). Whilst the P21A mutation is a naturally 
occurring polymorphism, position 46 is a site of phosphorylation could explain the 
reduction in Tat activity by almost 50%. Although we cannot assume which mutation had 
a more dominant effect. 
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Whilst the V4I mutation was seen in X205 plasma and CSF derived Tat, the plasma 
derived Tat from this patient harbored additional mutations; K24T, and S61R (Figure 3:5) 
which has been associated with a reduction in Tat activity. The presence of K24T and 
S61R mutations in X205P may be the cause of diversity differences within the plasma 
and CSF Tat in this subject (Figure 3:2). In addition, X205P had a significantly reduced 
LTR transactivation activity by 57% (± 11%) when compared to the consensus (Figure 
3:6) (p = 0.04). Whilst it is not clear which mutation in X205P had the more pronounced 
effect, this patient derived Tat sample synergistically reduced LTR activity. Furthermore, 
a large difference in LTR activity was observed between X205P and X205C (although not 
significant), however site directed mutagenesis is needed to target which mutation is 
responsible for this antagonistic effect of Tat between compartments.  
 
The biggest decrease in LTR activity across all patients was seen in A111C, that 
contained a triple mutation P21A, H29R and S31C, which reduced LTR activity by 61% 
(± 4%) (P = 0.002). Whilst H29R is previously reported to enhance relative LTR activity 
by site directed mutagenesis, the combination of H29R (enhancing), P21A (detrimental) 
and S31C (detrimental) resulted in a reduction of LTR activity. Which could imply that 
H29R is less dominant than the two detrimental mutations.  
 
Conversely, the greatest increase in Tat activity (although not statically significant) was 
seen in X214C that enhanced LTR activity by 18% (± 9%). Although X214C contained 
the V4I mutation, we cannot say for certain that the higher Tat activity in this patient is 
due to this particular mutation – more so that the opposite effect has been reported for 
the V4I mutation. This highlights the point that the synergistic effect of the combined 
mutations: V4I, K19Q, A21P, N23T, Y26F, H29F, A58T and P68L as seen within X214C 
(although not previously reported) could be driving higher LTR activity in this patient. 
Furthermore, single amino acid substitutions, followed by transactivation of each mutation 
will be needed to demonstrate synergy. Similarly, patient A96C had the V4I and D64N 
mutation that was only present in its CSF derived Tat, which also displayed an enhanced 
Tat ability to transactivate the LTR (not significant).  
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Lastly X233C with mutation P59S and A105C both had similarity in inducing the LTR by 
1% relative to the consensus, although no statistically significant. To summarize, 
approximately 66% of the samples were associated with a downregulation of LTR activity, 
17% had no difference and 17% upregulated LTR activity. 
 
 
Figure 3:6 Relative changes in LTR activity of patient derived Tat. The change in 
patient-derived LTR activity were determined relative to the HIV-1 subtype C consensus 
sequence (Con C) measured 24 hours after transfection. The pTargeT empty vector was 
included as a negative control. Values represented are the average from each sample 
performed in triplicate, and the error bars indicate the standard error of the mean (SEM). 
Statistical significance is indicated as follows: *, P < 0.05; **, P < 0.01. The colour encoded 
key represents the different Tat mutations found within patient the Tat derived. Patient ID 
were labeled either CSF derived (C) or plasma derived (P). 
 
Albeit, the reported mutations mentioned above does not necessarily prove that LTR 
activity was affected by those specific mutations alone. Rather the combination of these 
mutations within each Tat variant had resulted in reduced or enhanced LTR activity. 
Although this analysis included previously reported mutations, it remains to be determined 
if other mutations also contribute to the combined detrimental or enhancing activity of Tat 
and further site directed mutagenesis studies are needed for that. 
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To determine the impact of specific Tat mutations on HIV-1 LTR transactivation, we 
selected 5/12 (42%) of Tat sequences that contained the P21A mutation (amongst other 
mutations) for the Tat Transactivation assay. The relative change in LTR activity was 
calculated using the mean RLU of all patients with that mutation compared to the subtype 
consensus C.  Aforementioned the P21A polymorphism was reported to be associated 
with attenuated transactivation activity (Rossenkhan et al., 2013). Therefore, to determine 
the effect of the Tat variants with the P21A mutation to LTR activity in our cohort, five 
patient derived Tat with Alanine at position 21 (Ala21) and 7 Tat variants with Proline at 
position 21 (Pro21) irrespective of other mutations, were compared to a subtype C 
consensus. Our data shows all Tat variants with Ala21, were associated with significantly 
reduced Tat activity by 40% (± 8%) compared to the Consensus C (p =0.009) (Figure 
3:7). Although, the relative change in LTR activity in variants with a Pro21 was greater 
than variants with an Ala21, this trend was not statically significant (Figure 3:7). To 
increase the statistical significance of this result a greater sample size is warranted.   
 
Figure 3:7 Relative changes in LTR activity of a single Tat mutation. The change in 
LTR activity of the P21A mutation were determined relative to the HIV-1 subtype C 
consensus sequence (Consensus C) measured 24 hours after transfection. The pTargeT 
empty vector was included as a negative control. Values represented are the average 
taken from independent samples performed in triplicate, and the error bars indicate the 
standard error of the mean (SEM). Statistical significance is indicated as follows: *, P < 
0.05; **, P < 0.01. 
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Hence all individuals with a wildtype Pro21 had a higher LTR activity than individuals with 
an Ala21 which could implicate that mutation P21A irrespective of other mutations 
drastically reduces LTR activity. 
 
3.5. Tat LTR Activity correlated to markers of disease progression 
 
 
Lastly, to assess the relationship between Tat-mediated LTR activity and markers of 
disease progression such as viral load – a Pearson correlation coefficient and linear 
regression was done. Overall 3 analyses were done as seen in Figure 3:8: (A) correlating 
the relative LTR activity of all 12 patient derived Tat variants to viral load, (B) correlation 
to show the relationship of Tat variants with the Ala21 mutation to CSF viral load and (C) 
correlation to show the relationship of Tat variants with the wildtype Pro21 mutation to viral 
load.  
 
As observed in Figure 3:8A, all twelve patient derived Tat variants and their corresponding 
mutations were correlated to viral load (Table 6:1). Our data shows a positive yet non-
significant trend of Tat LTR activity and viral load in all 12 patient derived Tat. We next 
wanted to determine the correlation between the Ala21 and Pro21 mutation to viral load. 
Our results show that individuals with an Ala21 mutation showed a strong positive 
correlation with CSF viral load (r = 0.98; p = 0.003) (Figure 3:8B). However, this 
correlation does not show the effect of the Ala21 mutation on viral load, rather shows the 
relationship between transactivation ability in variants with the Ala21 mutation to patient 
viral load. Conversely, a weak positive correlation between Tat-mediated LTR activity and 
Tat variants with a Pro21 was observed (p = 0.39; r = 0.38) (Figure 3:8C).  Hence the 
Pearson’s correlation showed no concordance between data, indicating that Pro21 did not 
influence Tat mediated replication capacity.  
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Figure 3:8  Correlation of P21A Tat activity with viral load. The strength of association 
between Tat-mediated LTR activity (%) and viral load (copies/ml) were measured by a 
Pearson correlation coefficient and linear regression (solid line) for all twelve patient 
derived Tat (A), Tat variants with a 21A mutation (B) and Tat variants with a 21P mutation 
(C). The dotted lines represent the 95% confidence intervals. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
Whilst the linear relationship between the Tat-mediated luciferase expression and patient 
viral loads showed a positive trend and statistical significance for the Ala21 mutation, there 
are two major limitations; number of variants used in the correlation was small and greater 
a sample size would allow for a much more precise trend.  Secondly, the trend that when 
Ala21 mutation is held constant, viral load was linked to LTR transactivation could be 
confounded. Since Tat variants with the Ala21 mutation was occurring together with other 
mutations, therefore we cannot necessarily rule out that it is solely the mutation Ala21 that 
is responsible for the observed effect. 
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4. Discussion  
 
In our study we hypothesized that CNS specific Tat mutations were responsible for the 
high viral replication seen in the CNS of TBM patients. To test this hypothesis, we 
genetically and functionally characterized HIV-1 tat from 19 patients with TBM. Plasma 
and CSF derived tat sequences were successfully amplified and sequenced in all 19 
patients to determine genetic variation, our data showed that only 5 patients had 
differences between tat sequences in each compartment, whilst majority showed no 
difference between plasma and CSF sequences in each patient. Next, 12 different Tat 
variants, representative of reported mutations were cloned into a mammalian expression 
vector (pTargeT) and transfected into TZM-bl cells in order to determine the functional 
diversity of CNS derived Tat from TBM co-infected patients. Although our study confirmed 
that the previously reported Tat mutations impact its activity, none of these mutations 
were CSF specific. Taken together the data from our study rejects the hypothesis.  
 
The major aim was to characterize the effect of HIV-1 tat genetic variation and functional 
diversity on viral replication in the CNS of TBM and non-TBM patients. In 1998, a study 
reported that patients with TBM had the highest amount of HIV-1 RNA copies/ml in the 
CSF compared to  patients infected with other types of meningitis (Morris et al., 1998). 
Twenty years later the same observation was described with plasma and CSF HIV-1 viral 
load compared to other types of meningitis (Seipone et al., 2018). Hence the cause of 
what drives higher viral replication in the CNS of TBM patients is still unknown.  
 
Data from the phylogenetic analysis revealed that tat sequence pairs obtained from 
matched CSF and plasma of each patient clustered closely together with substantial 
genetic variation between compartments as was reflected by branch length differences. 
Although no tests were done for viral compartmentalisation between these two 
compartments, a prior study observed minimal compartmentalisation of tat sequences 
between CSF and plasma derived viruses in patients with HIV-associated dementia 
(HAD) (Cowley et al., 2011). Additionally, the unpublished data from our group have 
described similar results for env sequences from patient X195 in the TBM study, however 
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their data were unable to show sequence segregation between compartments of patients 
B98 and X223. Whilst we did not test for compartmentalisation, our data show that 2 
patients: X229 and A104 had no nucleotide differences between their respective plasma 
and CSF tat sequences, while 58% had evident differentiation between compartment 
which could indicate interpatient diversity. Furthermore, intermingling between TBM and 
non-TBM study participants were observed. Therefore, we reason that an interpatient 
diversity analysis would determine the precise diversity between sequences in the TBM 
and non-TBM groups (Figure 3:2). The analysis showed that TBM patients X205 and A96 
had the highest diversity when comparing their CSF to plasma sequences. Large 
differences in diversity between these groups were expected, since the viral loads in the 
TBM group were notably higher for plasma and CSF (p= 0.02) than the non-TBM group. 
However, overall there was no significant difference in diversity between the TBM and 
non-TBM groups. One of the limiting factors in this analysis could be due to the small 
sample size in the non-TBM group. 
 
Next, we reasoned that Tat differences could be more pronounced within a patient 
(intrapatient). Focusing on the TBM group an intrapatient diversity analysis was 
conducted to determine if tat sequences were more diverse in the CSF compartment than 
plasma of the same TBM patients. While CSF-derived tat sequences showed a slightly 
higher diversity compared to plasma there was no significant difference in tat sequences 
between these compartments. This was further confirmed when the allele frequencies of 
reported Tat mutations were represented in almost equal proportions within plasma and 
CSF Tat sequences (Table 3:1). Although HIV-1 compartmentalization has been 
previously observed between plasma and CSF from patients with opportunistic infections 
and HIV associated neurocognitive disorders (HAND), one plausible reason for the lack 
segregation within Tat variants in our current study could be due to pleocytosis of the 
blood brain barrier (BBB). Based on the published criteria for pleocytosis; normal values 
of CSF lymphocyte counts are 0 to 5 cells/µl in HIV-1 infected patients, while pleocytosis 
is designated as CSF lymphocyte counts >5 cells/µl (Fishman, 1992). In lieu of this, 
approximately 63% of the 16 individuals in the TBM group are undergoing lymphocytic 
pleocytosis (Table 6:1). Due to the large of amount of lymphocyte trafficking through the 
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BBB, the introduction of plasma derived viruses into the CNS or visa versa maybe the 
cause of no differentiation in sequences between plasma and CSF derived Tat.  
 
Whilst there was no significant difference between plasma and CSF derived Tat 
sequences, we assumed that mutations observed in our cohort may be responsible for 
the higher viral replication in TBM co-infected patients. The residues vital for Tat function 
are highly conserved these include; K28, K41, K50 and K51 (for acetylation); R56 and 
R57 (for TAR interaction); C22, C31, C34 and Y47 (for LTR transactivation), S16 and S46 
(for phosphorylation) (Ronsard et al., 2017). Almost all these residues remained highly 
conserved within our cohort. Interestingly our data show two subtype C specific 
mutations; a S57 (84%) is more prevalent than a  R57 (11%) as seen in subtype B, this 
is in line with other findings that suggest S57 coupled with E63 contribute to the higher 
activity of HIV-1C Tat (Kurosu et al., 2002). Likewise the C31S mutation has also been 
associated to HIV-1C Tat, however Tat activity between S31 and C31 are not significantly 
different (Kurosu et al., 2002).  
 
Our data shows that majority of amino acid substitutions observed in this cohort were 
between amino acids (aa) 1 – 48, which is in agreement with a previous report  
(Rossenkhan et al., 2013). Hence, aa: 1 – 48, comprise the first three domains of Tat 
making up the Tat activation domain, which is responsible for transactivation activity and 
CycT1 binding (Li et al., 2012). Although high variability in Tat is expected during a chronic 
infection, amino acid changes within the Tat activation domain (aa: 1 – 48) could impact 
the Tat mediated elongation, affecting the transactivation ability of Tat variants in our 
cohort.  
 
In the acidic domain both the V4I and P21A mutation were represented in the highest 
frequencies of 31% and 43% in TBM patients respectively, this could imply that they are 
naturally occurring polymorphisms. In agreement, two consecutive studies found the 
P21A mutation to be undergoing positive selection and unique to HIV-1C Tat (Neogi et 
al., 2012, Rossenkhan et al., 2013). Although, positive selection is used to detect amino 
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acid mutations increase reproductive fitness (Pan et al., 2006) , the 21A mutation had 
shown the greatest impact on reducing LTR activity by 88% (Rossenkhan et al., 2013).   
 
Additionally, sites 19 and 24 in the acidic domain and 29 in the cysteine domain, had high 
frequency variation at these positions. Although it is still unclear what causes the high 
variation at these particular positions, mutations K24S and H29R were previously 
confirmed by site directed mutagenesis to have a detrimental (K24S) and enhancing 
(H29R) effect on LTR activity (Rossenkhan et al., 2013). Hence further site directed 
mutagenesis needs to be done at mutations K19T, K24N and H29K which had high 
occurrence in our cohort. 
 
Within the cysteine domain, the reported S31C was observed in 19% of TBM patients. 
The C31S polymorphism is seen in approximately 90% of individuals with HIV-1C and is 
associated with reduced cytokine expression of monocytes circulating in the periphery  
(Rao et al., 2013).  Thus, the reversion mutation S31C that restores the C30C31 
dicysteine motif in HIV-1C as seen in our cohort, could impact Tat function. This is based 
on a previous report showing that the C30C31 motif allows for high cognitive impairment 
in patients with HAND (Mishra et al., 2008). 
 
In the core domain, the S46Y was observed in 13% and 6% of plasma and CSF 
sequences respectively,  since position 46 has been reported to aid in phosphorylation of 
Tat by cyclin-dependent kinase 2 (CDK2), mutations in this position attenuate Tat 
transactivation (Ammosova et al., 2006). The RNA binding domain (RBD) (composed of 
amino acids 49 – 57) contains nuclear localization signals that allow for efficient Tat-TAR 
binding. Therefore, amino acid changes observed in this region could have functional 
consequences on LTR activity. Mutations in the RBD include R52W, P59S and S61R, 
which were all previously associated with reduced Tat function, due to inefficient Tat-TAR 
binding resulting in a drastic decrease of viral transcription (Rossenkhan et al., 2013, 
Sivakumaran et al., 2007). Whilst there was limited segregation between CNS and 
plasma derived Tat, three patients A105, B98 and A96 did show CNS specific mutations 
including: T20P, H29K and D64N respectively. However since the D64N in PID A96 has 
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been reported to reduce TAR binding (Endo-Munoz et al., 2005), this Tat variant was 
selected for downstream analysis.  
 
Since Tat sequences demonstrated substantial sequence diversity in the Tat activation 
domain and low frequency mutations in the RBD, we sought to assess the functional 
effects of this sequence variation. In particular, we were interested in the functional 
capacity of previously reported mutations within Tat.  
 
The functional variation was measured using 10 different CSF Tat variants and 1 matched 
(plasma and CSF) sample, hence a total of 12 samples each representing a one or more 
reported mutations. Our findings suggest that there is heterogeneity in the ability of CNS 
derived Tat to transactivate the LTR, whilst 66% of the samples were associated with a 
downregulation of LTR activity, 17% had no difference – relative to the subtype C 
consensus and 17% upregulated LTR activity. Although majority of TBM patients 
demonstrated a restricted ability to transactivate the LTR, a functional comparison of CSF 
derived Tat from non-TBM patients would have been ideal to test our hypothesis. As prior 
research showed that CNS derived Tat had defective transactivation abilities when 
compared to non-HAD patients (Boven et al., 2007).  
 
In agreement with previous studies mutations: S46Y (detrimental) and S57R (enhancing) 
as seen in patient B98C had significantly reduced ability to transactivate the LTR by 46% 
(± 6%) (p = 0.007)(Ruiz, 2016, Sivakumaran et al., 2007). Whilst the functional capacity 
of each individual mutation within the B98C is not clear, the S46Y mutation which was 
previously associated with high attenuation of Tat activity exerted a more dominant effect. 
 
However, the biggest reduction in transactivation activity was seen in A111C which 
downregulated LTR activity by 61% (± 4%) (p = 0.002). The A111C sample was a triple 
mutant with P21A, H29R and S31C mutations. Although the A111C had the H29R 
mutation, reported to upregulate Tat activity, upon further analysis A111C also harbored 
an additional mutation K19R , previously described to impair transactivation activity 
(Kamori and Ueno, 2017). Therefore 3 out of the 4 mutations were associated with 
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detrimental Tat activity and could be responsible for the significant decrease in Tat 
transactivation. Additionally, K19T, P21A and S31C are also reported detrimental 
mutations. Although A111C and other patient derived Tat clones had a downregulated 
Tat activity – further mutagenesis studies are required to identify the specific residues 
involved.  
 
Aforementioned, patient A96 with the CNS specific D64N mutation had enhanced LTR 
activity by 9% (although not significant). This patient also had a reducing V4I mutation, 
which could imply that the D64N mutation exerted a more dominant effect, resulting in the 
upregulation of CNS derived Tat from this patient. Albeit, both site directed mutagenesis 
and a functional comparison against the A96 plasma compartment is needed to answer 
this question.  
 
To determine the effect of a single amino acid mutation, we measured the transactivation 
ability of the P21A mutation, observed in 5 patient derived Tat variants with Ala21 and 7 
patient derived Tat variants with Pro21, although it should be noted that these variants 
also contained other mutations as expected in during HIV-1C chronic infection. 
Consequently, without performing site directed mutagenesis we assessed the 
antagonistic effect of all patient derived Tat variants with the Ala21 mutation and variants 
with the Pro21 mutation (Figure 3:7). In agreement with a prior study our data shows that 
patient derived Tat variants with an Ala21, were associated with significantly reduced Tat 
activity by 40% (± 8%) compared to the Consensus C (p =0.009). Furthermore, the 
relative Tat activity of variants with the wildtype Pro21 was higher by 29% when compared 
to Tat variants with an Ala21 (although not statically significant). Since the P21A mutation 
is found within the Tat activation domain, it could suggest that variants with the mutation 
have impaired transcriptional elongation leading to inefficient gene expression and a low 
viral replication. Although this is the opposite of what we expected to find in the CNS of 
TBM patients – as the higher viral load seen in the CSF of TBM patients is indicative of a 
faster disease progression. Albeit a slower disease progression could imply a virulence 
trade-off for the virus to allow for longer survival in the host (Brown et al., 2012).  
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We next examined the relationship between Tat mediated LTR activity and viral load. In 
the first analysis (Figure 3:8A), our data shows a moderate positive, yet non-significant 
correlation between Tat transactivation activity and viral load. Next, reasoned that Tat 
variants with the Ala21 mutation and Pro21 mutation would show a clearer trend. Our data 
indicates a strong positive correlation (p = 0.003; r = 0.98) between Tat LTR activity and 
viral load, in all patients with the Ala21 mutation, which could suggest that the P21A 
mutation is a significant contributor to CSF viral load during chronic infection (Figure 
3:8B). However, to fully test this hypothesis, the matched plasma samples from these 
patients should also be correlated with viral load. In addition, the Pro21 mutation which 
had high transactivation activity in our cohort – showed no concordance with patient viral 
load (Figure 3:8C). This result could account for the moderate trend observed in Figure 
3:8A. 
 
To the best of our knowledge, this is the first study to look at CNS derived Tat from 
patients co-infected with TBM. Although there is paucity of data on the genetic diversity 
of the tat gene and its association with disease progression during chronic infection. Our 
data suggests that variation within CNS derived tat from patients co-infected with TBM 
may affect the functional capacity. Differences in LTR transactivation activity, was 
observed in different mutations within the 5 domains of tat exon 1. Whilst we expected 
that sequence variation within tat would result in a higher viral replication as seen in the 
CSF of patients with TBM, most of the amino acid differences resulted in a significantly 
reduced ability of Tat to transactivate the LTR. More so we observed that the detrimental 
mutation P21A was significantly correlated to viral load in the CNS compartment. 
Although we reject our hypothesis, we can still prove that Tat transactivation activity may 
contribute to viral load in chronic infection. 
 
Whilst measuring the genetic and functional diversity of Tat, did not fully correlate with 
the high viral production in the CNS, as implied by the baseline clinical data. There are 
various possible explanations that could account for the high viral load in the CSF of TBM 
patients. Firstly, high viral load in the CNS could be due to the elevated levels of cytokines 
interleukin-1β (IL-1β), IL-6, IL-8, IL-10, interferon gamma (IFN-γ) and TNF-α (Patel et al., 
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2011). In a recent study, identifying immunological biomarkers in the CSF between TBM 
and non-TBM infected individuals, elevated levels of IL-6, IL-8 and IL-10 were found to 
be  significantly higher  in the CSF of TBM patients compared to plasma (Seipone et al., 
2018). Therefore, it is possible that Tat could play an integral role in the activating and 
enhancing the immune response of TBM in HIV-1 co-infected persons leading to 
increased viral replication. Hence a better understanding of Tat immune dysregulation in 
the CNS could potentially inform therapeutic interventions and AIDS related pathologies. 
Secondly, since subtype C Tat that is well adapted for a subtype C LTR and the TZM-bl 
cell line used in our transfection assays contain a subtype B LTR, the resultant effect of 
some mutations could possibly be masked. While there are no TZM-bl cell lines available 
that contain an integrated subtype C LTR, this system to test the activity of our subtype 
C derived Tat. Thirdly, cells of the CNS including macrophages/monocytes, microglia, 
and astrocytes all produce their own transcription factors, hence high viral load in the 
CNS could be due to the result of cell specific transcription regulation and highly active 
transcription factors – regardless of the attenuation observed in Tat. 
 
The present study shows the importance of tat diversity in study participants chronically 
infected with TBM. However, there are few limitations that could be improved as well as 
future work that needs to be done.  
 
One of the biggest limitations in this study, as previously mentioned is the small sample 
size of the non-TBM group. Albeit, additional samples from non-TBM patients is difficult 
to obtain due to the invasive lumbar puncture procedure required for extraction of CSF. 
In addition, all tat plasma and CSF variants from both TBM and non-TBM participants 
should have been functionally assayed for a more thorough comparison as the 
representative sample set chosen could not accurately answer our question. Secondly, 
single genome amplification (SGA) would be a more precise measure to test for genetic 
variation and compartmentalization in tat sequences from the CSF and plasma of TBM 
patients as bulk PCR could account for potential bias from recombination and resampling 
of DNA (Butler et al., 2009). Moreover, this would have allowed for stronger comparisons 
of previously reported and novel mutations to be identified.  Lastly, whilst TZM-bl cells are 
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an adherent cell line and could be transfected and easily measured due to luc driven by 
the LTR promoter, it doesn’t necessarily represent the population of infected cells that are 
able to cross the blood brain barrier. Hence transfection into cells of the 
monocytes/macrophage lineage, endothelial cells and SVG astrocytes could be used to 
investigate functional activity of Tat. In addition, there was disparity is fully understanding 
the transactivation data as each sequence had more than one mutation, therefore we 
cannot say for certain that a particular mutation causes and decrease/increase in LTR 
activity. Further site directed mutagenesis will be needed to fully answer that question.  
 
Future work recommendations include: electrophoretic mobility shift assay (EMSA) to 
further study the Tat-TAR interaction and relative protein expression of Tat variants with 
reported mutations as identified in this cohort. This study provides evidence that Tat is a 
key regulator of viral gene transcription and ultimately disease progression. In essence, 
modern practical approaches that target the cellular transcription factors including p-TEFb 
elongation and NF-kB LTR activation could provide valuable clues to guide research on 
vaccine development and viral eradication.  
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6. Appendix 
 
6.1 Baseline Clinical Data 
 
Table 6:1 Baseline Clinical Data of TBM and non-TBM study participants  
 
TBM 
ARV NAÏVE 
LAB NO: Plasma Viral load (copies/ml) 
CD4+ Count 
(copies/µl) 
CSF Viral load 
(copies/ml) 
Lymphocyte Count 
(copies/µl) 
B98 1489556 71 672812 111,6 
X214 943314 94 6129219 10,72 
X223 1710603 78 2599081 32 
X233 163590 32 > 10000000 6,4 
X195 1008150 200 1462385 2,8 
X201 99078 14 713295 2 
B103 38409 50 8133 4 
X215 94407 274 1264491 5,68 
X221 243480 72 630291 2,4 
A96 109677 441 35766 6,56 
A104 866178 347 53640 4,8 
A105 28921 677 11454 22,08 
A68 66041 85 2975556 13,44 
A111 960561 199 262777 4,8 
A130 519029 158 30175 7,44 
X205 390650 117 75258 11,44 
Non-TBM 
ARV NAÏVE 
LAB NO: Plasma Viral load (copies/ml) 
CD4+ Count 
(copies/µl) 
CSF Viral load 
(copies/ml) 
Lymphocyte Count 
(copies/µl) 
X229 102025  36 14230 0,24 
B129 213260 532 5109 5,92 
X235 4317 113  10631 2,16 
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6.2 HIV-1C DNA sequences from TBM cohort  
 
>TatCConsensus_1-216 
ATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAAAACT 
GCTTGTAATAAGTGTTATTGTAAACACTGTAGCTATCATTGTCTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCGCTCCTCCA 
AGCAGTGAGGATCATCAAAATCCTATATCAAAGCAA 
 
>A96_PLASMA_1-216 
ATGGAGCTAGTAGATCCTGACCTAGCGCCCTGGCACCATCCAGGAAGTCAGCCTAAAACT 
CCTTGCAATAAATGCTATTGTAAATGCTGTAGTTATCATTGTTTAGCTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAACGACGAAGCACTCCTCCA 
AGCAGTGAGAGCCATCAAAATCATATATCAAAGCAG 
 
>A96_CSF_1-216 
ATGGAGCTAGTAGACCCTGACCTAGCGCCCTGGCACCATCCAGGAAGTCAGCCTAAAACT 
CCTTGCAATAAATGCTATTGTAAACACTGTAGCTATCATTGTTTAGCTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAACGACGAAGCACTCCTCCA 
AGCAGTGAGAATCATCAAAATCCTATATCAAAGCAG 
 
>A103_PLASMA 
ATGGAGCCAGTAGATCYTAACYTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTACAACT 
CCTTGTAATACGTGMTACTGTAAACAYTGCAGCTACCATTGTCTAGTTTGCTTTCAGACC 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCRCTCCTCCA 
AGCAGTGAGGATCATCAAAATCCTCTACCAAASCAG 
 
>A103_CSF 
ATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTACAACT 
CCTTGTAATACGTGCTACTGTAAACACTGCAGCTACCATTGTCTAGTTTGCTTTCAGACC 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCACTCCTCCA 
AGCAGTGAGGATCATCAAAATCCTCTACCAAAGCAG 
 
>A111_PLASMA 
ATGGAGCCAGTAGATACTAAACTAGAGCCATGGAATCACCCAGGGAGTCAGCCTAGAACT 
GCTTGTAATAAGTGTTATTGCAAAAGATGYTGCTACCACTGTTTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCACTCCTCCA 
AGCAGTGAGGATCATCAAAATCTTGTATCAAAGCAG 
 
>A111_CSF 
ATGGAGCCAGTAGATACTAAACTAGAGCCATGGAATCACCCAGGGAGTCAGCCTAGAACT 
GCTTGTAATAAGTGTTATTGCAAAAGATGYTGCTACCACTGTTTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACRAASCACTCCTCCA 
AGCAGTGAGGATCATCAAAATCTTGTATCAAAGCAG 
 
>A130_PLASMA 
ATGGAGCCAATAGATCCTAACMTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAAAACC 
CCTTGTACTAAATGCTATTGTAAATACTGTAGCTACCACTGTCTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACARCGACGAAGCACTCCTCCA 
AGCAGTGAGGATCATCARAATCTTATATCAAAGCAG 
 
>A130_CSF 
ATGGAGCCAATAGATCCTAACATAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAAAACC 
CCTTGTACTAAATGCTATTGTAAATACTGTAGCTACCACTGTCTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACARCGACGAAGCACTCCTCCA 
AGCAGTGAGGATCATCAGAATCTTATATCAAAGCAG 
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>A68_PLASMA 
ATGGAGCCAGTAGAYCCTAGCCTAGAGCCCTGGAAMCAYCCAGGAAGTCAGCCTCAAACT 
GCTTGTAATAATTGTTATTGTAARAGATGTAGCTATCATTGTCTAGTTTGCTTTCAGAAA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGTGGAGACAGCGACGAGGACATCCTCCG 
AGCAGTGAGAGCCATCAAAATCYTGTATCAAAGCAG 
 
>A68_CSF 
ATGGAGCCAGTAGAYCCTAGCCTAGAGCCCTGGAAMCAYCCAGGAAGTCAGCCTCAAACT 
GCTTGTAATAATTGTTATTGTAARAGATGTAGCTATCATTGTCTAGTTWGCTTTCAGAAA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGTGGAGACAGCGACGAGGACATCCTCCG 
AGCAGTGAGAGCCATCAAAATCYTGTATCAAAGCAG 
 
>B98_PLASMA 
ATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAAAACT 
GCTTGTAATCCATGCTATTGTAAACGTTGTAGCTATCATTGTTTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTACTATGGCAGGAAGAAGCGGAGACAACGACGCAGAGCTCCTCCG 
AGCAGTGAGGATCATCAAGATCTTGTATCAAAGCAG 
 
>B98_CSF 
ATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAACCTAAAACT 
GCTTGTAATCCATGCTATTGTAAAAAATGTAGCTATCATTGTTTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTACTATGGCAGGAAGAAGCGGAGACAACGACGCAGAGCTCCTCCG 
AGCAGTGAGGATCATCAAGATCTTATATCAAAGCAG 
 
>A104_PLASMA 
ATGGAGCCAGTAGATCCTGACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAAAACT 
CCTTGTAATAAGTGCTTTTGTAAACACTGTAGTTATCATTGTCTAGTTTGCTTYCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGTCAGCGACGAAGCACTCCTTCA 
AGCAGTAAAGATCATCAAAATCCTGTACCAAAGCAG 
 
>A104_CSF 
ATGGAGCCAGTAGATCCTGACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAAAACT 
CCTTGTAATAAGTGCTTTTGTAAACACTGTAGTTATCATTGTCTAGTTTGCTTYCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGTCAGCGACGAAGCACTCCTTCA 
AGCAGTAAAGATCATCAAAATCCTGTACCAAAGCAG 
 
>A105_PLASMA 
ATGGAGCCAATAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTACAWCT 
CCTTGTAATTCTTGTTATTGCAAAAAGTGTAGCTATCATTGTCTAGTTTGCTTTCATACG 
AAAGGCTTAGGCATTTCCTATGSCAGGAAGAAGCGGAGACAGCGACGAAGCGCTCCTCCA 
GGCAGTAAGGATCATCAAAATCCTCTACCAAAGCAG 
 
>A105_CSF 
ATGGAGSCAATAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTACACCT 
CCTTGTAATTCTTGTTATTGCAAAAAGTGTAGCTATCATTGTCTAGTTTGCTTTCAGACG 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCGCTCCTCCA 
GGCAGTAAGGATCATCAAAATCCTCTACCAAAGCAG 
 
>A129_PLASMA 
ATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCCAAAACT 
CCTTGTAATAAGTGCTATTGTAAACACTGCAGCTATCATTGTTTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCACTCCTCCA 
AGCAGTGAGGATCATCAAAATCTTATATCAAAGCAG 
 
 
 
81 
 
>A129_CSF 
ATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCCAAAWCT 
CCTTGTAATAAGTGCTATTGTAAACACTGCAGCTATCATTGTTTAGTTTGYTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGMGGAGACAGCGACGAAGCACTCCTCCA 
AGCAGTGAGGATCATCAAAATCTTATATCAAAGCAG 
 
>X195_PLASMA 
ATGGAGCCAATAGATCCTAAYCTAGAGCCCTGGAACCACCCAGGRAGTCAGCCTGAAACT 
GCTTGTAATACTTGTTATTGTAAATACTGTAGTTTCCATTGTCTAGCTTGCTTTCAGAAA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAAACAGCGACGAAGCGCTCCTCCT 
AGCAGTGAGGACCATCAAAATCCTGTACCAAAGCAG 
 
>X195_CSF 
ATGGAGCCAATAGATCCTAACCTAGAGCCCTGGAACCACCCAGGRAGTCAGCCTGAAACT 
GCTTGTAATACTTGTTATTGTAAATACTGTAGTTTCCATTGTCTAGCTTGCTTTCAGAAA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAARCAGCGACGAAGCGCTCCTCCT 
AGCAGTGAGGACCATCAAAATCCTGTACCAAAGCAG 
 
>X201_PLASMA 
ATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAATCATCCAGGAAGTCAGCCTAAAACT 
CCTTGTAATAAATGCTTTTGTAAAAGCTGTAGCTACCACTGTCTAGTTTGCTTTCAGACG 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCACTCCTTCA 
AGCAGTGAGGATCATCAAAATCCTATATCAAAGCAG 
 
>X201_CSF 
ATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAATCATCCAGGAAGTCAGCCTAAAACT 
CCTTGTAATAAATGCTTTTGTAAAAGCTGTAGCTACCACTGTCTAGTTTGCTTTCAGACG 
AAAGGCTTAGGCTTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCACTCCTTCAA 
GCAGTGAGGATCATCAAAATCCTATATCAAAGCAG 
 
>X205_PLASMA 
ATGGAGCCAATAGATCCTAACCTAGAACCCTGGAATCATCCAGGAAGTCAGCCTGAAACT 
CCTTGTAATACATGTTATTGCAAAAAATGTTGCTATCATTGCTTAGCTTGCTTTCAGACG 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCGCTCCTCAG 
CGCAGTGAGGATCATCAAGATCTTGTATCAAAGCAG 
 
>X205_CSF 
ATGGAGCCAATAGATCCTAACCTAGAACCCTGGAATCATCCAGGAAGTCAGCCTGAAACT 
CCTTGTAATAAATGTTATTGTAAAAAATGCTGCTATCATTGCTTAGCTTGCTTTCAGACG 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCGCTCCTCAG 
AGCAGTGAGGATCATCAAGATCTTGTATCAAAGCAG 
 
>X214_PLASMA 
ATGGAGCCAATAGATCCTAAYTTAGAACCTTGGAACCACCCAGGAAGTCAGCCTCAAACT 
CCTTGTACTAAGTGCTTTTGTAAATTCTGTAGCTATCATTGTCTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCACTCCTCCA 
AGCAGTGAGGATCATCAAAATCTTATATCAAAGCAG 
 
>X214_CSF 
ATGGAGCCADTAGATCCTAACTTAGAACCTTGGAACCACCCAGGAAGTCAGCCTCAAACT 
CCTTGTACTAAGTGCTTTTGTAAATTCTGTAGCTATCATTGTCTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCACTCCTCCA 
AGCAGTGAGGATCATCAAAATCTTATATCAAAGCAG 
 
>X215_PLASMA 
ATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAARACT 
GCTTGTAGTCCGTGTTATTGCAAAAAATGTAGCTATCATTGTCTAGTTTGCTTTCAGACA 
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AAAGGCTTAGGCATTTACTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCGCTCCTCCA 
AGCAATAAGGACCATCAKAATCCTCTATCAAAGCAG 
 
>X215_CSF 
ATGGAGCCAGTAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAAGACT 
GCTTGTAGTCCGTGTTATTGCAAAAAATGTAGCTATCATTGTCTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCGCTCCTCCA 
AGCARTAARGAYCATCAAAATCCTCTATCAAAGCAG 
 
>X221_PLASMA 
ATGGAGCCAGTAGATCCTAGCCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAAAACT 
GCTTGCAATAATTGCTATTGTAAAWGCTGTAGCTACCATTGTCTAGTTTGCTTTCAGAMA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAACGAMGAMGCACTCCTCCA 
AGYRGTGAGGATCATCAAAATCYTATATCAAAGCAG 
 
>X221_CSF 
ATGGAGCCAGTAGATCCTAGCCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAAAACT 
GCTTGCAATAATTGCTATTGTAAATYCTGTAGCTACCATTGTCTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGACGCACTCCTCCA 
AGCAGTGAGGATCATCAAAATCYTATATCAAAGCAG 
 
>X223_PLASMA 
ATGGAGCCYGTAGATTCTAACCTAGAGCCCTGGAATCATCCAGGAAGTCAGCCAAAAACT 
GCTTGTAACGGTTGCTATTGTAAAAGATGCTGCTACCATTGTCTAGTTTGCTTTCAGAAA 
AAAGGCTTARGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCGCTCCTCCA 
AGCAGKGAGGATCATCAAAATCCTATATCAAAGCAG 
 
>X223_CSF 
ATGGAGCCCGTAGATTCTAACCTAGAGCCCTGGAATCATCCAGGAAGTCAGCCAAAAACT 
GCTTGTAACGGTTGCTATTGTAAAAGATGCTGCTACCATTGTYTAGTTTGCTTTCAGAAA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCGCTCCTCCA 
AGCAGTGAGGATCATCAAAATCCTRTATCAAAGCAG 
 
>X229_PLASMA 
ATGGAGCCAGTAGATCCTAACTTAGAGCCCTGGAACCATCCAGGAAGTCAGCCCACAACT 
CCTTGTAATAAATGCTATTGTAAACACTGTAGCTACCATTGTCTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCACTCCTCCA 
AGCAGTGAGGATCATCAAAATCCTGTATCAAAGCAG 
 
>X229_CSF 
ATGGAGCCAGTAGATCCTAACTTAGAGCCCTGGAACCATCCAGGAAGTCAGCCCACAACT 
CCTTGTAATAAATGCTATTGTAAACACTGTAGCTACCATTGTCTAGTTTGCTTTCAGACA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGAAGCACTCCTCCA 
AGCAGTGAGGATCATCAAAATCCTGTATCAAAGCAG 
 
>X233_PLASMA 
ATGGAGCCAGTAGATCCTAACCTAGAGYCCTGGAACCATCCAGGAAGTCAGCCTAACACT 
CCTTGTACTAAGTGCTATTGTAAAAAATGTAGCTATCATTGTCTAGTTTGCTTTCAGAAA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACGGCGACGAAGCCCTTCTCCA 
AGCAGTAAGGATCATCAAAATCTTGTATCAAAGCAG 
 
>X233_CSF 
ATGGAGCCAGTAGATCCTAACCTAGAGTCCTGGAACCATCCAGGAAGTCAGCCTAACACT 
CCTTGTACTAAGTGCTATTGTAAAAAATGTAGCTATCATTGTCTAGTTTGCTTTCAGAAA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACGGCGACGAAGCCCTTCTCCA 
AGCAGTAAGGAYCATCAAAATCTTGTATCAAAGCAG 
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>X235_PLASMA 
ATGGAGCCAATAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAGTACT 
CCTTGCAATAACCGCTATTGTAAACACTGTAGCTACCATTGTTTAGCTTGCTTTCAGAGA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGCAGCACTCCTCCA 
AGCAATAAGGATCATCAAAATCCTGTATCAAAGCAG 
 
>X235_CSF 
ATGGAGCCAATAGATCCTAACCTAGAGCCCTGGAACCATCCAGGAAGTCAGCCTAGTACT 
CCTTGCAATAACTGCTATTGTAAACACTGTAGCTACCATTGTCTAGCTTGCTTTCAGAGA 
AAAGGCTTAGGCATTTCCTATGGCAGGAAGAAGCGGAGACAGCGACGCAGCACTCCTCCA 
AGCAATAAGGATCATCAAAATCCTGTATCAAAGCAG 
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